var title_f4_60_5056="Posterior tibial tendonitis";
var content_f4_60_5056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse sonogram of posterior tibial tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse sonogram of the posterior tibial tendon as it passes near the medial maleolus of a patient with rheumatoid arthritis shows an irregularly echoing widening due to proliferative synovitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5056=[""].join("\n");
var outline_f4_60_5056=null;
var title_f4_60_5057="Spinal BMD with testosterone";
var content_f4_60_5057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Spinal bone density in hypogonadal men receiving testosterone therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increases in bone mineral density, as measured by quantitative computed tomography, are shown in 72 men with hypogonadism receiving long-term testosterone therapy. The circles indicate men whose first measurement was made before initiation of testosterone therapy, the squares indicate men already receiving testosterone therapy at their first measurement. The dark shaded area indicates the range of high fracture risk, the light shaded area indicates the range of intermediate fracture risk, and the unshaded area indicates the range of low fracture risk. The greatest increase in bone density occurred in the first year of therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Behre, HM, Kliesch, S, Leifke, F, et al, J Clin Endocrinol Metab 1997; 82:2386.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5057=[""].join("\n");
var outline_f4_60_5057=null;
var title_f4_60_5058="Patient information: Blisters (The Basics)";
var content_f4_60_5058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/53/1874\">",
"         Patient information: Dermatitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/21/22865\">",
"         Patient information: Heat rash (prickly heat) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/3/3122\">",
"         Patient information: Poison ivy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/28/29122\">",
"         Patient information: Pyoderma gangrenosum (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/43/25266\">",
"         Patient information: Skin burns (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/20/23874\">",
"         Patient information: Sunburn (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/38/32354\">",
"         Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/59/6068\">",
"         Patient information: Poison ivy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32625\">",
"         Patient information: Skin burns (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Blisters (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/blisters-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H105136953\">",
"      <span class=\"h1\">",
"       What are blisters?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blisters are fluid-filled bumps on the skin. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105136968\">",
"      <span class=\"h1\">",
"       What causes blisters?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many things can cause blisters, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Something rubbing or pressing against the skin &ndash; This might happen from wearing a tight-fitting shoe or gripping a tool.",
"       </li>",
"       <li>",
"        Bad burns, often from something very hot (like a boiling water or a stove) or a sunburn",
"       </li>",
"       <li>",
"        Allergic reactions to something that touches the skin, such as poison ivy or poison oak",
"       </li>",
"       <li>",
"        Problems with the body&rsquo;s infection-fighting system (called the &ldquo;immune system&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105136985\">",
"      <span class=\"h1\">",
"       What are the symptoms of blisters?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include one or more fluid-filled bumps on the skin. The fluid is usually clear.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105137000\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you are not sure what caused your blisters or if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blisters in your mouth, near your eyes, or in or near your anus or genital area",
"       </li>",
"       <li>",
"        Blisters all over your body",
"       </li>",
"       <li>",
"        Painful blisters",
"       </li>",
"       <li>",
"        Blisters with pus inside",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105137015\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you need to see a doctor or nurse for your blisters, he or she might do tests to find the cause of your blisters. This might include taking a sample of your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105137032\">",
"      <span class=\"h1\">",
"       How should I take care of a blister?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To care for a blister caused by something rubbing or pressing the skin or a burn, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash the area with soap and water.",
"       </li>",
"       <li>",
"        Do not pop or poke the blister with a sharp object. Opening the blister makes it more likely to get infected and slows healing.",
"       </li>",
"       <li>",
"        If the blister pops, keep the area clean and cover with a bandage to protect it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Do not scratch blisters from poison ivy. If you have poison ivy, your doctor might recommend medicine to ease itching or other bothersome symptoms.",
"     </p>",
"     <p>",
"      Most blisters heal in about a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105137047\">",
"      <span class=\"h1\">",
"       Can blisters be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting blisters if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear shoes that fit properly.",
"       </li>",
"       <li>",
"        Use gloves or protective padding when working with tools.",
"       </li>",
"       <li>",
"        Wear a hat, protective clothing, and sunscreen when out in the sun.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105137062\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=see_link\">",
"       Patient information: Skin burns (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"       Patient information: Sunburn (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=see_link\">",
"       Patient information: Poison ivy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=see_link\">",
"       Patient information: Dermatitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"       Patient information: Pyoderma gangrenosum (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/21/22865?source=see_link\">",
"       Patient information: Heat rash (prickly heat) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"       Patient information: Skin burns (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=see_link\">",
"       Patient information: Poison ivy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"       Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/60/5058?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83674 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5058=[""].join("\n");
var outline_f4_60_5058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105136953\">",
"      What are blisters?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105136968\">",
"      What causes blisters?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105136985\">",
"      What are the symptoms of blisters?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105137000\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105137015\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105137032\">",
"      How should I take care of a blister?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105137047\">",
"      Can blisters be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105137062\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=related_link\">",
"      Patient information: Dermatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/21/22865?source=related_link\">",
"      Patient information: Heat rash (prickly heat) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=related_link\">",
"      Patient information: Poison ivy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=related_link\">",
"      Patient information: Poison ivy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=related_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=related_link\">",
"      Patient information: Skin burns (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=related_link\">",
"      Patient information: Skin burns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=related_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5059="Macular stain - neck";
var content_f4_60_5059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macular stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous patch is present on the posterior scalp and neck of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5059=[""].join("\n");
var outline_f4_60_5059=null;
var title_f4_60_5060="Bacteria in resting zone";
var content_f4_60_5060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacteria in the resting zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Habitual colonic bacteria in the healthy wild-type mouse are diffusely distributed and have similar high concentrations at the center of stool and in the \"germinal\" zone indicating normal function of colonic bioreactor. B) Bacteria are suppressed in a 28-week-old mouse with IL-10 deficiency, at the center of stool, but are unchanged at the \"germinal\" zone. The reaction is general and is indicative for any disturbance of the colonic bioreactor. Bacteroides is orange, Eubacterium rectale is red, all other bacteria are green (x400). The suppression of bacteria precedes the inflammation. The animals had no symptoms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5060=[""].join("\n");
var outline_f4_60_5060=null;
var title_f4_60_5061="Mirabegron: Drug information";
var content_f4_60_5061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mirabegron: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/2/42019?source=see_link\">",
"    see \"Mirabegron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15167819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myrbetriq&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14585338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       3",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14965739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Overactive bladder (OAB):",
"     </b>",
"     Oral: Initial: 25 mg once daily; efficacy is observed within 8 weeks for 25 mg dose. May increase to 50 mg once daily based on individual patient efficacy and tolerability.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14965740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14965741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-89 mL/minute or eGFR 30-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute or eGFR 15-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): Do not exceed 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute or eGFR &lt;15 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) or patients requiring hemodialysis: Not recommended (has not been studied)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14965742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment (Child-Pugh Class A): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Child-Pugh Class B): Do not exceed 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh Class C): Not recommended (has not been studied)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15167820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myrbetriq&trade;: 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14965578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14965840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally without regard to food. Swallow the tablet whole with water; do not chew, divide, or crush.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14585330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15049290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Cardiovascular: Hypertension (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (2% to 3%), xerostomia (3%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (3% to 6%), cystitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (4%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): ALT/AST increased, atrial fibrillation, breast cancer, cerebrovascular accident, GGT increased, glaucoma, LDH increased, leukocytoclastic vasculitis, lung cancer, nephrolithiasis, osteoarthritis, palpitations, prostate cancer, Stevens-Johnson syndrome, urinary retention, vaginal infection, vulvovaginal pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14965591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14965598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood pressure effects: Dose-related increases in blood pressure were observed in clinical trials (mean increase of ~0.5-1 mm Hg compared to placebo in overactive bladder patients treated with 50 mg); monitor blood pressure periodically during therapy. Not recommended for use in patients with severe uncontrolled hypertension (SBP &ge;180 and/or DBP &ge;110 mm Hg); if used in patients with controlled and less severe hypertension, use with caution and monitor blood pressure closely; exacerbation of pre-existing hypertension has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bladder flow obstruction: Use with caution in patients with bladder outlet obstruction (BOO); the risk of urinary retention may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; dosage adjustment is required in patients with moderate hepatic impairment. Use is not recommended in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required in patients with severe renal impairment. Use is not recommended in ESRD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antimuscarinics: Use with caution in patients taking concomitant antimuscarinic medications; concomitant use may increase the risk of urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP2D6 substrates: Mirabegron is a moderate CYP2D6 inhibitor which may increase the concentration of CYP2D6 substrates (eg, metoprolol, desipramine); if a medication with a narrow therapeutic index metabolized by CYP2D6 (eg, thioridazine, flecainide, propafenone) is coadministered, monitoring and dosage adjustment of the concomitant agent may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Females: Systemic exposure is increased in females compared to males; however, dosage adjustments are not necessary or recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15163957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15163955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desipramine: Mirabegron may increase the serum concentration of Desipramine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Mirabegron may increase the serum concentration of Digoxin.  Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Mirabegron may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: Mirabegron may diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Mirabegron may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Mirabegron may enhance the therapeutic effect of Solifenacin. This may result in acute urinary retention. Mirabegron may increase the serum concentration of Solifenacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14965618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Coadministration with a high-fat meal decreased C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC by 45% and 17%, respectively. Coadministration with a low-fat meal decreased C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC by 75% and 51%, respectively. However, safety and efficacy were unaffected by food intake, and mirabegron may be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14965584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14965585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14965586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14965590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion of mirabegron into breast milk is expected. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Myrbetriq Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (90): $750.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $750.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14965843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure periodically during therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betanis (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14965672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mirabegron, a beta-3 adrenergic receptor agonist, activates beta-3 adrenergic receptors in the bladder resulting in relaxation of the detrusor smooth muscle during the urine storage phase, thus increasing bladder capacity. At usual doses, mirabegron is believed to display selectivity for the beta-3 adrenergic receptor subtype compared to its affinity for the beta-1 and -2 adrenoceptor subtypes. Data have shown that beta-adrenoceptors, predominately the beta-3 subtype, mediate detrusor smooth muscle tone and promote the storage function of the human bladder.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14965682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Efficacy is seen within 8 weeks; steady state achieved within 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : ~1670 L (following I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~71%; binds mainly to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive metabolism via multiple pathways (eg, dealkylation, oxidation, glucuronidation, amide hydrolysis) via multiple enzymes (eg, UGT, esterase, CYP3A4, CYP2D6); two major pharmacologically inactive metabolites produced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 29% to 35% (following 25 mg and 50 mg oral dosing, respectively); bioavailability is dose-dependent; C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC are higher in females compared to males",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (radiolabeled drug: 55%; unchanged drug: ~25%); feces (radiolabeled drug: 34%; unchanged drug: 0%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Michel MC, Ochodnicky P, Homma Y, et al, \"&beta;-Adrenoceptor Agonist Effects in Experimental Models of Bladder Dysfunction,\"",
"      <i>",
"       Pharmacol Ther",
"      </i>",
"      , 2011, 131(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/60/5061/abstract-text/21510978/pubmed\" id=\"21510978\" target=\"_blank\">",
"        21510978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85675 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5061=[""].join("\n");
var outline_f4_60_5061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15167819\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14585338\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965739\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965740\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965741\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965742\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15167820\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965578\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965840\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14585330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15049290\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965591\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965598\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163957\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163955\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965618\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965584\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965585\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965586\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965590\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570442\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965843\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721653\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965672\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965682\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85675|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/2/42019?source=related_link\">",
"      Mirabegron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5062="Giant papillary conjunctivitis";
var content_f4_60_5062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Giant papillary conjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Pedram Hamrah, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5062/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/60/5062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). GPC is a noninfectious inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. It is characterized by foreign-body sensation on the upper tarsus, associated with formation of \"giant\" (&gt;1 mm) papillae. GPC is reviewed here. Other contact lens-related complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=see_link\">",
"     \"Complications of contact lenses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VKC and AKC are chronic, bilateral, and severe forms of allergic inflammation affecting the ocular surface. These two relatively uncommon types of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly. VKC and AKC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=see_link\">",
"     \"Vernal keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=see_link\">",
"     \"Atopic keratoconjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seasonal and perennial allergic conjunctivitis, the most common forms of ocular allergy, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. Toxic conjunctivitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6452?source=see_link\">",
"     \"Toxic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GPC is most commonly associated with wearing of contact lenses, and is seen more frequently with soft, hydrogel lenses rather than rigid, gas permeable lenses (RGP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Approximately 1 to 5 percent of soft contact lens wearers have clinical signs of GPC, and the prevalence is about 10-fold less in rigid lens wearers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/1\">",
"     1",
"    </a>",
"    ]. This difference in prevalence is probably because allergens adhere more readily to the surface of soft contact lenses. Additional factors that influence the incidence of GPC in contact lens wearers include wearing time of contact lenses, cleaning routine (frequency and types of solutions), and duration of contact lens wear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/4\">",
"     4",
"    </a>",
"    ]. The average onset of GPC after start of contact lens wear is 10 to 20 months for soft contact lenses and 22 to 90 months for rigid lenses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, symptoms may occur as early as three weeks after the start of contact lens wear.",
"   </p>",
"   <p>",
"    Other foreign substances that can trigger GPC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ocular prostheses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Extruded scleral buckles [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glaucoma filtering blebs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cyanoacrylate glue [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Band keratopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposed sutures [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GPC affects predominantly young adults, because of the association with contact lenses. There is no gender predilection. A history of atopy is also associated with GPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/11\">",
"     11",
"    </a>",
"    ]. The peak distribution of GPC is in the spring and fall, possibly due to increased pollen allergens in the air during this time of the year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of GPC involves both mechanical and immunologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/13\">",
"     13",
"    </a>",
"    ]. Debris that can build up on the contact lens surface over time is associated with GPC. This debris may be recognized as foreign to the mucous membranes of the conjunctiva, thereby initiating a reaction (a combination of type I and type IV hypersensitivity) with repeated immunologic presentation. Additionally, trauma from blinking over a foreign substance (such as a contact lens, prosthesis, or suture barb) can provide a port of entry for antigens and induce an immune response.",
"   </p>",
"   <p>",
"    The combination of mechanical trauma and immune reaction with release of inflammatory mediators leads to increased lymphocytes, papillary formation, fibroblast proliferation, and collagen production. These factors lead to giant papillae formation.",
"   </p>",
"   <p>",
"    The total number of inflammatory cells in the conjunctiva is elevated in GPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/13\">",
"     13",
"    </a>",
"    ]. Mast cells, eosinophils, and basophils are increased in biopsies of papillae and are found in both the conjunctival epithelium and the substantia propria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/14\">",
"     14",
"    </a>",
"    ]. Cells similar to membranous epithelial cells (M cells) in mucosa-associated lymphoid tissue are found in elevated numbers in the conjunctiva of patients with GPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/15\">",
"     15",
"    </a>",
"    ]. These cells are involved in the binding, uptake, and translocation of antigens to underlying lymphocytes and antigen presenting cells.",
"   </p>",
"   <p>",
"    Tear levels of IgE, and in some cases IgM and IgG are elevated in patients with GPC compared with contact lens wearers without GPC and with normal controls. The IgE is produced locally and recognizes the lens material or allergic material contaminants that have adhered to the lens. In addition, levels of leukotriene C4 levels are elevated in tears of GPC patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/16\">",
"     16",
"    </a>",
"    ]. Increased numbers of CD4+ T cells and levels of inflammatory cytokines, particularly IL-4, IL-6, soluble IL-6 receptor, and eotaxin, are also seen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms may precede overt signs of GPC and are initially mild at onset. Early symptoms include mild irritation and itching, as well as slight mucus production. If untreated, symptoms gradually progress and may include mucus overproduction (most often noted first thing in the morning), more intense itching, foreign body sensation, discomfort upon insertion of lenses, blurry vision, and increased awareness of contact lenses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/3\">",
"     3",
"    </a>",
"    ]. Complete intolerance to wearing contact lenses can develop in severe cases. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Signs include enlarged papillae on the upper tarsus, mucus production, conjunctival hyperemia, eyelid thickening, and sometimes ptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/3\">",
"     3",
"    </a>",
"    ]. In the early stages, papules are rarely larger than 0.3 mm. The papillae often reach 1 to 2 mm in size as the disease progresses (",
"    <a class=\"graphic graphic_picture graphicRef76072 \" href=\"UTD.htm?10/27/10672\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74752 \" href=\"UTD.htm?16/32/16896\">",
"     picture 2",
"    </a>",
"    ). Protein deposits of unknown origin are often visible on the contact lens surface. Frequently, signs and symptoms do not perfectly correlate and vary depending on the inciting stimulus. Dryness and blepharitis may exacerbate GPC, as with other allergic conditions affecting the eye. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical histology of GPC is thickened and irregular conjunctival epithelium covering giant papillae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/21\">",
"     21",
"    </a>",
"    ]. Epithelial cells show polymorphism and polymegathism. There is a greater number of conjunctival goblet cells, which appears to be due to the increased conjunctival surface area covering the papillae. GPC is characterized by increased numbers of eosinophils, basophils, mast cells, lymphocytes, and plasma cells in the substantial propria, and to a lesser degree in the epithelium. The infiltration of these cells demonstrates the immune-mediated features of GPC. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is made by eliciting a history of contact lens (or prosthesis, suture knot, etc) intolerance, and by everting the upper lid and observing enlarged papillae. Both the size and pattern of papillae can vary, as noted previously. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    GPC can be classified into four stages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/2\">",
"     2",
"    </a>",
"    ], although symptoms and signs do not always correlate, and there is much variation among patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In stage I, symptoms include mild mucus discharge after sleeping and mild itching after lens removal. There are no signs or papillae at this stage.",
"     </li>",
"     <li>",
"      In stage II, there is an increase in mucus production and itching, an awareness of the lens, blurred vision, and the development of upper tarsal papillae.",
"     </li>",
"     <li>",
"      In stage III, there is severe mucus production and itching. The contact lens itself becomes coated with debris. The papillae are increased in number and size. The contact lens may have excessive movement caused by blinking and \"grabbing\" of the lens by the enlarged papillae. At this stage, there is a reduction in contact lens wearing time.",
"     </li>",
"     <li>",
"      In stage IV, all signs and symptoms are severe, and the contact lenses are worn only briefly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes the other types of allergic conjunctivitis and toxic conjunctivitis (see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above). The main differentiating feature of GPC is that there is presence of a foreign substance in the eye, such as contact lenses. GPC can be differentiated from seasonal and perennial conjunctivitis if that giant papillae do not form in those types of conjunctivitis. Papillary hypertrophy is seen in vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and occasionally in toxic conjunctivitis. However, it typically occurs in the inferior fornix in patients with AKC, VKC occurs in a different patient population, and toxic conjunctivitis is associated with use of ocular medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=see_link\">",
"     \"Vernal keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=see_link\">",
"     \"Atopic keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6452?source=see_link\">",
"     \"Toxic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of GPC usually resolve in less than one week if the source of mechanical irritation is removed. In patients with GPC triggered by contact lenses, improving cleaning and storage of the lenses to prevent protein adherence, reducing the wearing time, increasing the frequency of lens replacement, and changing the type",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    design of the lenses may help. The vast majority of patients who comply with treatment will be able to successfully resume contact lens use.",
"   </p>",
"   <p>",
"    Contact lens wear should be discontinued for two to four weeks to allow the inflammation to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. Old contact lenses and",
"    <span class=\"nowrap\">",
"     storage/cleaning",
"    </span>",
"    solutions containing preservatives should be thrown out. When possible, the patient should restart contact lens usage with a new pair of lenses. Lens cleaning agents, along with storing and rinsing solutions, should all be preservative-free, since hypersensitivity reactions to preservatives can contribute to the inflammatory reaction. However, homemade saline solutions are not advised due to the risk of bacterial contamination. Daily disinfection with 3 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    is recommended over other types of disinfection. Enzymatic cleaning of lenses should be performed three times a week or even daily to reduce lens debris [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lenses should be replaced at least every three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/23\">",
"     23",
"    </a>",
"    ]. Changing the type and design of contact lenses may also be beneficial. A switch from extended wear to daily wear (or daily wear to disposable wear) may help to decrease the accumulation of debris and allergens on the contact lens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Changing from soft contact lenses to RGP contact lenses may help if other approaches do not succeed.",
"   </p>",
"   <p>",
"    A contact lens \"holiday\" should be initiated if symptoms persist or recur. Lenses can be reintroduced approximately two to three weeks after symptoms resolve.",
"   </p>",
"   <p>",
"    Frequent use of preservative-free,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    can provide relief of mild symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25784?source=see_link&amp;anchor=H17#H17\">",
"     \"Dry eyes\", section on 'Artificial tears'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical antihistamines, mast cell stabilizers, and combination agents can all provide relief of acute itching and reduce eye rubbing by reducing histamine release.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    has been shown in observational studies to promote resolution of early GPC signs and symptoms when combined with improved lens hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/21,26-28\">",
"     21,26-28",
"    </a>",
"    ]. However, advanced GPC does not respond to cromolyn sodium alone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/25/33168?source=see_link\">",
"     Olopatadine",
"    </a>",
"    is the primary treatment of choice among most clinicians, although there are no observational studies or randomized trial of olopatadine in GPC.",
"   </p>",
"   <p>",
"    Topical \"soft\" steroids that have a lower risk than other corticosteroids of causing side effects, such as increased intraocular pressure may be necessary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39684?source=see_link\">",
"     Loteprednol",
"    </a>",
"    etabonate was shown to be effective in improving signs and symptoms of GPC in most patients in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5062/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Topical corticosteroids should only be used in severe, acute cases of GPC, such as in patients who fail to respond to several weeks of the therapies mentioned previously. In addition, they should be used judiciously and for no longer than four to six weeks. Tapering of corticosteroids is usually done over a two-week period. If the steroid drops have been used for longer than six weeks, they should be tapered more slowly and in correlation with the duration of their usage. Patients on topical corticosteroids should be managed by an ophthalmologist because of the risk of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant papillary conjunctivitis (GPC) is a noninfectious inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GPC is characterized by foreign-body sensation on the upper tarsus, associated with formation of \"giant\" (&gt;1 mm) papillae (",
"      <a class=\"graphic graphic_picture graphicRef76072 \" href=\"UTD.htm?10/27/10672\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef74752 \" href=\"UTD.htm?16/32/16896\">",
"       picture 2",
"      </a>",
"      ). Patients often have intense pruritus and increased mucus production. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is made by eliciting a history of intolerance of contact lenses or another foreign substance in the eye, and by everting the upper lid and observing enlarged papillae. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of GPC usually resolve in less than one week if the source of mechanical irritation is removed. In patients with GPC triggered by contact lenses, improving cleaning and storage of the lenses to prevent protein adherence, reducing the wearing time, increasing the frequency of lens replacement, and changing the type",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      design of the lenses may help. The vast majority of patients who comply with treatment will be able to successfully resume contact lens use. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of a topical mast cell inhibitor or dual acting mast cell inhibitor and antihistamine for patients who do not improve with removal of the inciting agent and other nonpharmacologic measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend a short course of topical corticosteroids in patients who do not respond to mast cell inhibitors and who have severe disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/1\">",
"      Binder PS. The physiologic effects of extended wear soft contact lenses. Ophthalmology 1980; 87:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/2\">",
"      Allansmith MR, Korb DR, Greiner JV, et al. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 1977; 83:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/3\">",
"      Elhers WH, Donshik PC. Giant papillary conjunctivitis. Curr Opin Allergy Clin Immunol 2008; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/4\">",
"      Forister JF, Forister EF, Yeung KK, et al. Prevalence of contact lens-related complications: UCLA contact lens study. Eye Contact Lens 2009; 35:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/5\">",
"      Srinivasan BD, Jakobiec FA, Iwamoto T, DeVoe AG. Giant papillary conjunctivitis with ocular prostheses. Arch Ophthalmol 1979; 97:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/6\">",
"      Robin JB, Regis-Pacheco LF, May WN, et al. Giant papillary conjunctivitis associated with an extruded scleral buckle. Case report. Arch Ophthalmol 1987; 105:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/7\">",
"      Vengayil S, Vanathi M, Dada T, et al. Filtering bleb-induced giant papillary conjunctivitis. Cont Lens Anterior Eye 2008; 31:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/8\">",
"      Carlson AN, Wilhelmus KR. Giant papillary conjunctivitis associated with cyanoacrylate glue. Am J Ophthalmol 1987; 104:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/9\">",
"      Heidemann DG, Dunn SP, Siegal MJ. Unusual causes of giant papillary conjunctivitis. Cornea 1993; 12:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/10\">",
"      Sugar A, Meyer RF. Giant papillary conjunctivitis after keratoplasty. Am J Ophthalmol 1981; 91:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/11\">",
"      Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/12\">",
"      Begley CG, Riggle A, Tuel JA. Association of giant papillary conjunctivitis with seasonal allergies. Optom Vis Sci 1990; 67:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/13\">",
"      Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/14\">",
"      Allansmith MR, Korb DR, Greiner JV. Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology 1978; 85:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/15\">",
"      Zhong X, Liu H, Pu A, et al. M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis. Arch Immunol Ther Exp (Warsz) 2007; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/16\">",
"      Irke&ccedil; MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm 1999; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/17\">",
"      Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy 1999; 29:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/18\">",
"      Bozkurt B, Akyurek N, Irkec M, et al. Immunohistochemical findings in prosthesis-associated giant papillary conjunctivitis. Clin Experiment Ophthalmol 2007; 35:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/19\">",
"      Shoji J, Inada N, Sawa M. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol 2006; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/20\">",
"      Moschos MM, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses. Cornea 2004; 23:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/21\">",
"      Donshik PC, Ballow M, Luistro A, Samartino L. Treatment of contact lens-induced giant papillary conjunctivitis. CLAO J 1984; 10:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/22\">",
"      Richard NR, Anderson JA, Tasevska ZG, Binder PS. Evaluation of tear protein deposits on contact lenses from patients with and without giant papillary conjunctivitis. CLAO J 1992; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/23\">",
"      Donshik PC, Porazinski AD. Giant papillary conjunctivitis in frequent-replacement contact lens wearers: a retrospective study. Trans Am Ophthalmol Soc 1999; 97:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/24\">",
"      Donshik PC. Giant papillary conjunctivitis. Trans Am Ophthalmol Soc 1994; 92:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/25\">",
"      Hayes VY, Schnider CM, Veys J. An evaluation of 1-day disposable contact lens wear in a population of allergy sufferers. Cont Lens Anterior Eye 2003; 26:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/26\">",
"      Meisler DM, Berzins UJ, Krachmer JH, Stock EL. Cromolyn treatment of giant papillary conjunctivitis. Arch Ophthalmol 1982; 100:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/27\">",
"      Iwasaki W, Kosaka Y, Momose T, Yasuda T. Absorption of topical disodium cromoglycate and its preservatives by soft contact lenses. CLAO J 1988; 14:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/28\">",
"      Kruger CJ, Ehlers WH, Luistro AE, Donshik PC. Treatment of giant papillary conjunctivitis with cromolyn sodium. CLAO J 1992; 18:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/29\">",
"      Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008; 92:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/30\">",
"      Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997; 123:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/31\">",
"      Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5062/abstract/32\">",
"      Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993; 12:313.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5553 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5062=[""].join("\n");
var outline_f4_60_5062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5553|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/27/10672\" title=\"picture 1\">",
"      Giant papillary conjunctivitis in contact lens wearer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/32/16896\" title=\"picture 2\">",
"      Giant papillae in giant papillary conjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=related_link\">",
"      Atopic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=related_link\">",
"      Complications of contact lenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6452?source=related_link\">",
"      Toxic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=related_link\">",
"      Vernal keratoconjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5063="Pediculosis corporis hyperpigmentation";
var content_f4_60_5063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Pediculosis corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple excoriations and prominent hyperpigmentation in a patient with pediculosis corporis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5063=[""].join("\n");
var outline_f4_60_5063=null;
var title_f4_60_5064="Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes";
var content_f4_60_5064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Beth N Peshkin, MS, CGC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Claudine Isaacs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5064/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/60/5064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germline (inherited) genetic mutations are associated with less than 10 and 15 percent of breast and ovarian cancers, respectively, regardless of family history [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Of those associated with a germline mutation, the majority of hereditary breast and ovarian cancers are associated with mutations in one of two genes, breast cancer type 1 and 2 susceptibility genes (BRCA1 and BRCA2) (",
"    <a class=\"graphic graphic_table graphicRef79724 \" href=\"UTD.htm?29/43/30395\">",
"     table 1",
"    </a>",
"    ). Other less common hereditary cancer syndromes, such as Li-Fraumeni and Cowden syndromes, are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef66808 \" href=\"UTD.htm?11/38/11884\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with familial cancers, genetic risk assessment can help quantify risk and inform decisions about screening and methods for cancer prevention. The benefit of genetic risk assessment services on patient outcomes, including perceived risk of cancer and psychological distress was evaluated in a 2012 systematic review that included five studies and over 1900 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/5\">",
"     5",
"    </a>",
"    ]. In this descriptive analysis, formal genetic risk assessment was consistently associated with an improvement in psychological well-being, reduction in distress, and a decrease in the level of worry.",
"   </p>",
"   <p>",
"    Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndrome and the psychosocial issues surrounding genetic testing are reviewed here. BRCA1 and BRCA2 mutations and genetic testing for these mutations, hereditary cancer syndromes associated with increased susceptibility to breast cancer (in women and men) and ovarian cancer, and management of patients with hereditary breast and ovarian cancer syndrome are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133230805\">",
"    <span class=\"h1\">",
"     FORMAL GENETIC RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most centers, the process of genetic risk assessment includes three steps: pre-test counseling, genetic testing, and post-test counseling. These are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pre-test counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of pre-test counseling is to provide an individual with a genetic risk assessment based on their personal and family history, and to discuss the options for and implications of genetic testing. Mathematical models may be used to provide patients with estimates of cancer risks and the likelihood of testing positive for a gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H106889210#H106889210\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Predictive models'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-test genetic counseling (performed by trained",
"    <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/genetics/directory\">",
"     genetic counselors",
"    </a>",
"    or nurse specialists in genetics) provides an opportunity to discuss potential benefits, risks (clinical, psychological, and social), and limitations of genetic testing with the patient. It also provides them with information needed to think about the potential impact the test results may have for themselves and their relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our center we usually perform pre-test counseling in-person. However, telephone counseling and various adjuncts for counseling (including electronic-based",
"    <span class=\"nowrap\">",
"     educational/decision",
"    </span>",
"    aids) are often used as well [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. It is important to assess individuals for distress or anxiety, and they may be better served by in-person pre- and post-test counseling whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pedigree evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of pre-test counseling is a detailed review of the patient's past medical history and family history, which should include information on maternal and paternal relatives, preferably covering at least three generations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic counseling and testing\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of the pedigree for features of a possible hereditary cancer provides the basis for accurate risk assessment. However, the ability to discern a pattern of hereditary cancer may be hampered by small family size, the presence of few women in the family, or limited family history information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H8#H8\">",
"     \"Genetic counseling and testing\", section on 'Limitations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients overestimate the contribution of single mutations to breast and ovarian cancer, and unaffected women with a positive family history of breast cancer tend to overestimate their risk of developing cancer. Therefore, it is important to convey to patients an impression about whether the features of their family history are suggestive of an inherited susceptibility to cancer and if so, what the likelihood is that genetic testing will provide a clinically meaningful result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetic counseling and testing\", section on 'Risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Benefits and limitations of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No individual can know how he or she will react when informed of genetic testing results. Nevertheless, discussing the benefits and limitations of genetic testing beforehand can prepare a patient emotionally, and enable him or her to mobilize coping skills, support systems, and informational resources before the actual results are communicated.",
"   </p>",
"   <p>",
"    The potential benefits of testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced uncertainty about cancer risks.",
"     </li>",
"     <li>",
"      Reassurance if the test is considered a true negative (ie, the test is negative when there is a known deleterious mutation in a close relative).",
"     </li>",
"     <li>",
"      For patients without cancer, it facilitates informed decision-making about cancer surveillance and cancer prevention, including the use of endocrine therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      risk-reducing surgery for women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"       \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"       \"Screening for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with cancer, it facilitates informed decision making about risk reduction for second malignancies (eg, the role of a bilateral mastectomy in women with BRCA-positive ovarian cancer) and may influence decisions about treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing may also provide information about risk to family members, particularly one's siblings and children, especially if the test is positive. Test results may also affect reproductive choices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risks of testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic testing may not provide a definitive answer about cancer risk. Individuals who test positive for a mutation cannot be told that they will definitively develop cancer or when cancer will develop. Results may be uninformative (ie, no mutation found after extensive genetic testing) or yield one or more variants of uncertain significance (a mutation that can be benign or deleterious, but cannot be classified either way at present). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H10#H10\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Uninformative findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although there are no physical risks associated with genetic testing, the psychological impact may be significant, although most individuals who decide to undergo testing cope very well with the information. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H23#H23\">",
"       \"Genetic counseling and testing\", section on 'Psychosocial issues'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many individuals are also concerned about the possibility of genetic discrimination. Reassuringly, legislation exists at both the state and federal levels to protect against genetic discrimination. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic discrimination'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the complexities and challenges inherent in the decision to undergo genetic testing, it is not surprising that some high-risk patients do not pursue genetic testing, even after counseling. The reasons most commonly given for declining genetic testing are lack of health insurance, fear of insurance discrimination, emotional effects on self and family, and concerns about test accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/8\">",
"     8",
"    </a>",
"    ]. Alternatively, patients may be motivated by psychological distress to seek genetic testing; additional reasons to pursue genetic testing include the desire to utilize genetic information for medical decision making and to better inform family members of cancer risks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of genetic testing in general and specifically for hereditary breast and ovarian cancer syndrome, ie, BRCA1 and BRCA2 mutation testing, including information on testing criteria, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Post-test counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-test counseling provides an opportunity to review information about hereditary breast and ovarian cancer syndromes and provides an opportunity for patients to understand and assimilate their results. It also provides an opportunity to review available options to reduce risk. As individuals from lower risk families are tested, it is not uncommon to see short term increases in distress around the time of disclosure. However, this and other negative effects appear to resolve with time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    An important component of post-test counseling is to inform patients of the implications of the test result to themselves and their family members, identify at-risk individuals based upon the pedigree structure, and encourage sharing of this information with relatives. Clinicians should document that patients are informed about who (in their family) is at risk and what the potential implications are. In addition, patients should be provided with information for their relatives (eg, copies of test result and information on how to find a genetic counselor). Finally, they should stipulate when if ever they would disclose results without patient&rsquo;s consent.",
"   </p>",
"   <p>",
"    Physicians should be aware that a patient may refuse to voluntarily disclose results, which may raise professional conflicts between two competing ethical obligations: the duty to protect patient privacy and autonomy versus the duty to disclose for the purpose of preventing future harm. Until such time as clear legal obligations are defined, physicians should consult with medical geneticists, genetic counselors, or bioethicists in the event that patients do not provide consent to share information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H25#H25\">",
"     \"Genetic counseling and testing\", section on 'Disclosure to family members'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In some families, such disclosure may result in discord among relatives, while in other cases, relatives may be quite receptive to the information [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Nevertheless, studies of family disclosure have found that most individuals, carriers and non-carriers, do share their test results with at-risk relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. All patients who are faced with disseminating BRCA test results to family members should have access to resources that can aid in family communication, such as letters or educational materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H922951389\">",
"    <span class=\"h3\">",
"     Patients with a positive test",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is normal for patients who test positive for a genetic mutation to experience some level of distress, anxiety, or sadness, most studies suggest that these patients do not suffer adverse psychological consequences of receiving a positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Although they may experience short term increases in distress around the time of disclosure, this and other negative effects tend to dissipate with time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/18\">",
"     18",
"    </a>",
"    ]. Indeed, individuals from high-risk families may worry about the possibility of having a mutation, which may be no less distressing than having that belief confirmed. However, individuals who did not expect to receive positive results, such as those women with a limited family history, may be more vulnerable to adverse psychological sequelae of genetic testing. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H922951418\">",
"    <span class=\"h3\">",
"     Patients with a negative test",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not unusual for patients who test negative for a known familial mutation to feel a degree of \"survivor guilt\" for being spared what other relatives have to endure. However, overall, studies suggest that women who test negative experience significant declines in distress (ie, depression, anxiety, cancer worry) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/26,30\">",
"     26,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H922951425\">",
"    <span class=\"h3\">",
"     Patients with an uniformative result",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because identifiable BRCA mutations account for less than 25 percent of hereditary breast cancers, the majority of women undergoing BRCA testing receive an uninformative result (ie, a negative result in an affected high-risk individual who is the first to be tested in a specific family). At least one study suggests that significantly higher levels of distress and worry followed an uninformative test result if women had a personal history of cancer (p&le;0.001) and a higher risk based on their pedigree analysis (p&le;0.005) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H10#H10\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Uninformative findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H922951609\">",
"    <span class=\"h1\">",
"     APPROACHING PATIENTS WHO DECLINE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although psychosocial concerns may deter some high-risk individuals from genetic testing, controlled outcome studies have demonstrated no evidence of major mental health risks in those who pursue testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/25-27,32-36\">",
"     25-27,32-36",
"    </a>",
"    ]. Therefore, these patients should be encouraged to proceed with testing. For high-risk individuals who decline genetic testing, referral (or ongoing) genetics counselling and access to information regarding genetic testing should be offered because they appear to be at risk for depression, particularly if such individuals exhibited high stress levels at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/37\">",
"     37",
"    </a>",
"    ]. Even if they ultimately do not proceed with testing, these individuals should be followed by their primary care providers for psychological distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GENETIC DISCRIMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the primary sources of concern about potential harm in patients undergoing genetic testing stems from inadequate protection of privacy and the potentially negative impact of genetic testing on employment and obtaining health insurance. Fear of genetic discrimination is a common reason for declining genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/38\">",
"     38",
"    </a>",
"    ]. Fortunately, privacy laws regarding confidentiality of health information should provide reassurance to patients that genetic test results will not be used in a discriminatory manner [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the Federal Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurers and employers from asking or requiring a person to take a genetic test, and from using genetic test information in decisions about employment or health insurance (including eligibility, coverage, underwriting, or premium-setting) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, while GINA extends protection to people covered in group and the individual health insurance markets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/42\">",
"     42",
"    </a>",
"    ], it has the following limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GINA does not address the use of genetic information in other insurance markets (eg, long term care, life, and disability insurance) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/43\">",
"       43",
"      </a>",
"      ]. The regulation of insurance markets outside of health insurance is determined at the state level [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GINA does not apply to employers with fewer than 15 employees, the US military (and the TRICARE military health system), the Indian Health Service, the Veterans Health Administration, or the Federal Employees Health Benefits Program [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2014, the Affordable Care Act will prohibit variations in premiums based on health status and genetic information [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, legislation and policies regarding the use of genetic information in insurance and employment in other countries vary considerably, and are often less explicit than what has been adopted in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].&nbsp;This variability is due in part to the fact that insurance is largely employer-based in the US, whereas this is not the case in countries with universal health care.",
"   </p>",
"   <p>",
"    Although the potential for genetic discrimination in health care is considerably less in nations with government-sponsored health care systems, the British government has issued a moratorium prohibiting insurers from using genetic test results to set premiums for certain life insurance, long-term care, and income protection policies that is in effect until 2017 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5064/abstract/8,49\">",
"     8,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If privacy has been breached, individuals must rely upon anti-discrimination legislation to protect them. Within the United States, the Americans with Disabilities Act (ADA) protects employees from bias. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44857776\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling helps patients at risk for hereditary cancer syndromes make an informed decision about undergoing genetic testing and provides an opportunity to contemplate the impact of the test results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at risk for familial breast or ovarian cancer should undergo formal genetic risk assessment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pre-test counseling provides individuals with a genetic risk assessment based on their personal history and family history, and an opportunity to discuss the potential benefits, risks, and limitations of genetic testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pre-test counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important that patients are aware of federal and state genetic discrimination laws to help ease potential concerns that may keep some patients from undergoing genetic testing. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic discrimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-test counseling provides an opportunity to review information about hereditary breast cancer and management options and helps patients understand and assimilate their results. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Post-test counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/1\">",
"      Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/2\">",
"      Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/3\">",
"      Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2012 file://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/5\">",
"      Hilgart JS, Coles B, Iredale R. Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev 2012; 2:CD003721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/6\">",
"      Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/7\">",
"      Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010; 102:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/8\">",
"      Lerman C, Shields AE. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nat Rev Cancer 2004; 4:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/9\">",
"      Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/10\">",
"      Green MJ, Peterson SK, Baker MW, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA 2004; 292:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/11\">",
"      Wakefield CE, Meiser B, Homewood J, et al. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat 2008; 107:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/12\">",
"      Platten U, Rantala J, Lindblom A, et al. The use of telephone in genetic counseling versus in-person counseling: a randomized study on counselees' outcome. Fam Cancer 2012; 11:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/13\">",
"      Peshkin BN, Demarco TA, Graves KD, et al. Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 2008; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/14\">",
"      Wang C, Gonzalez R, Milliron KJ, et al. Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet A 2005; 134A:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/15\">",
"      Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/16\">",
"      McGivern B, Everett J, Yager GG, et al. Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med 2004; 6:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/17\">",
"      Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012; 118:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/18\">",
"      Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009; 28:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/19\">",
"      McInerney-Leo A, Biesecker BB, Hadley DW, et al. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. Am J Med Genet A 2005; 133A:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/20\">",
"      Green RM, Thomas AM. Whose gene is it? A case discussion about familial conflict over genetic testing for breast cancer. J Genet Couns 1997; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/21\">",
"      Loud JT, Weissman NE, Peters JA, et al. Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol 2006; 24:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/22\">",
"      Segal J, Esplen MJ, Toner B, et al. An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers. Am J Med Genet A 2004; 125A:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/23\">",
"      Patenaude AF, Dorval M, DiGianni LS, et al. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 2006; 24:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/24\">",
"      Bradbury AR, Dignam JJ, Ibe CN, et al. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol 2007; 25:3705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/25\">",
"      Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003; 118A:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/26\">",
"      Schwartz MD, Peshkin BN, Hughes C, et al. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002; 20:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/27\">",
"      van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003; 21:3867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/28\">",
"      Braithwaite D, Emery J, Walter F, et al. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/29\">",
"      van Roosmalen MS, Stalmeier PF, Verhoef LC, et al. Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. Am J Med Genet A 2004; 124A:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/30\">",
"      Kinney AY, Bloor LE, Mandal D, et al. The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. Cancer 2005; 104:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/31\">",
"      van Dijk S, Timmermans DR, Meijers-Heijboer H, et al. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 2006; 24:3672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/32\">",
"      Lodder L, Frets PG, Trijsburg RW, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet 2001; 98:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/33\">",
"      Meiser B, Butow P, Friedlander M, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer 2002; 38:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/34\">",
"      Bish A, Sutton S, Jacobs C, et al. No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches. Genet Med 2002; 4:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/35\">",
"      Brain K, Norman P, Gray J, et al. A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. Br J Cancer 2002; 86:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/36\">",
"      Lobb EA, Butow PN, Barratt A, et al. Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes. Br J Cancer 2004; 90:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/37\">",
"      Lerman C, Hughes C, Lemon SJ, et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998; 16:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/38\">",
"      Allain DC, Friedman S, Senter L. Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act. Fam Cancer 2012; 11:637.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Labor, Department of Health and Human Services, Equal Employment Opportunity Commission, and Department of Justice. Genetic Information and the Workplace. file://www.dol.gov/oasam/programs/history/herman/reports/genetics.htm (Accessed on February 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/40\">",
"      Hudson KL, Holohan MK, Collins FS. Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008; 358:2661.",
"     </a>",
"    </li>",
"    <li>",
"     Genetics and Federal Law https://www.disabilityrightslegalcenter.org/about/documents/Genetics-National2011.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/42\">",
"      Korobkin R, Rajkumar R. The Genetic Information Nondiscrimination Act--a half-step toward risk sharing. N Engl J Med 2008; 359:335.",
"     </a>",
"    </li>",
"    <li>",
"     Genetic discrimination. file://www.genome.gov/10002077.",
"    </li>",
"    <li>",
"     Regulation of genetic information in life, long term care, and disability insurances: ",
"50 state survey. https://www.disabilityrightslegalcenter.org/about/documents/GeneticsStateSurveyFinal.pdf (Accessed on February 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/45\">",
"      Hudson KL. Genomics, health care, and society. N Engl J Med 2011; 365:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/46\">",
"      Van Hoyweghen I, Horstman K. European practices of genetic information and insurance: lessons for the Genetic Information Nondiscrimination Act. JAMA 2008; 300:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/47\">",
"      Godard B, Raeburn S, Pembrey M, et al. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet 2003; 11 Suppl 2:S123.",
"     </a>",
"    </li>",
"    <li>",
"     file://archive.eurordis.org/article.php3?id_article=1805 (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5064/abstract/49\">",
"      Morrison PJ. Insurance, unfair discrimination, and genetic testing. Lancet 2005; 366:877.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 740 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5064=[""].join("\n");
var outline_f4_60_5064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44857776\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1133230805\">",
"      FORMAL GENETIC RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pre-test counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pedigree evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Benefits and limitations of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Post-test counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H922951389\">",
"      - Patients with a positive test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H922951418\">",
"      - Patients with a negative test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H922951425\">",
"      - Patients with an uniformative result",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H922951609\">",
"      APPROACHING PATIENTS WHO DECLINE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GENETIC DISCRIMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44857776\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/43/30395\" title=\"table 1\">",
"      Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/38/11884\" title=\"table 2\">",
"      Breast cancer genes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5065="Microbiology, pathogenesis, and epidemiology of Campylobacter infection";
var content_f4_60_5065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Ban M Allos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5065/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/60/5065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacters are small gram-negative bacteria first recognized as causes of abortion in cattle and sheep in the early twentieth century [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/1\">",
"     1",
"    </a>",
"    ]. A few decades later, the organism (originally called Vibrio) was reported as an occasional cause of illness in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1973, a new genus, Campylobacter, was designated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/3\">",
"     3",
"    </a>",
"    ]. It was not until the 1980s that the full impact of Campylobacter infections on human health began to be appreciated; they are now known to be a leading cause of acute diarrhea worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Campylobacter spp are common commensals in the gastrointestinal tract of animals, especially poultry; thus, animal-to-human transmission of infections occurs frequently. The microbiology, pathogenesis, and epidemiology of Campylobacter infection will be reviewed here. The clinical features and treatment of Campylobacter infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacters belong to a distinct group of specialized gram-negative bacteria designated rRNA superfamily VI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/4\">",
"     4",
"    </a>",
"    ]. Apart from the genus Campylobacter, the group also contains Arcobacter and Helicobacter. Arcobacters are closely related to campylobacters, and some cause intestinal infection in humans. Helicobacter pylori is well known as a cause of gastritis and peptic ulcer disease, but there are other Helicobacter species that cause infection of the human gut. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19368?source=see_link\">",
"     \"Infection with less common Campylobacter species and related bacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A feature common to all these bacteria is that they are adapted to colonize the surface of the mucous membranes of the alimentary and reproductive tracts. This adaptation is reflected in their morphology. The combination of spiral shape and long polar flagella leads to rapid motility that enables the organisms to \"corkscrew\" their way through mucus with a facility denied to conventional bacteria (",
"    <a class=\"graphic graphic_picture graphicRef62173 \" href=\"UTD.htm?20/28/20929\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most members of this group are microaerophilic, or partially anaerobic, and most undergo transformation into coccoid forms when exposed to adverse conditions, especially oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/5\">",
"     5",
"    </a>",
"    ]. These appear to be degenerative forms, but some believe they are potentially dormant forms capable of long survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/6\">",
"     6",
"    </a>",
"    ]. Although some campylobacters can survive in cold water for several weeks, even months, they are not necessarily in coccal form. In general, these bacteria are fragile and easily destroyed by heat, desiccation, acidity, irradiation, and disinfectants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Campylobacter species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many Campylobacter spp (\"atypical\" Campylobacters) have now been recognized to cause human disease, as these organisms have been isolated from stool samples using filtration and antibiotic-free culture medium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/7\">",
"     7",
"    </a>",
"    ]. Eighteen species of Campylobacter are currently recognized and new species are being discovered with regularity. Most have been isolated at some time from humans. However, the most important species to cause human disease are Campylobacter jejuni and Campylobacter coli, the principal causes of Campylobacter enteritis. The remainder of this topic review will be devoted to infection with these two species.",
"   </p>",
"   <p>",
"    C. jejuni has two subspecies: C. jejuni subsp jejuni and C. jejuni subsp doylei. The latter is a less common and a more fastidious organism than the former. For the sake of brevity, we will refer to C. jejuni subsp jejuni simply as C. jejuni.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Detection in the laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard method for detecting campylobacters in clinical specimens is by culture. However, it is possible to make a presumptive identification by the microscopic examination of fresh stools of patients who are in the acute phase of diarrheal illness (eg, using dark-field, phase-contrast, or stained smears). This is less sensitive than culture (50 compared to 94 percent) and is not practiced routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/8\">",
"     8",
"    </a>",
"    ]. Gram's stain is even less sensitive. C. jejuni appears as faint, gram-negative curved rods (",
"    <a class=\"graphic graphic_picture graphicRef78674 \" href=\"UTD.htm?14/34/14895\">",
"     picture 2",
"    </a>",
"    ). Direct microscopy of stool specimens may also reveal the presence of red blood cells or neutrophils, which are present in 75 percent of patients with Campylobacter enteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The culture of Campylobacter spp is optimally performed using selective media and incubation in a gas mixture of 5 to 10 percent oxygen, 1 to 10 percent carbon dioxide, and ideally some hydrogen (",
"    <a class=\"graphic graphic_picture graphicRef69842 \" href=\"UTD.htm?34/43/35518\">",
"     picture 3",
"    </a>",
"    ). The optimum incubation temperature for C. jejuni and C. coli is 42 to 43&ordm;C; as a result, the term \"thermophilic\" campylobacters is sometimes applied to these species. In laboratories with limited facilities, successful results can be obtained by incubation in a candle extinction jar, provided that the plates are incubated at this higher temperature.",
"   </p>",
"   <p>",
"    Growth is usually visible after overnight incubation, but two days are needed before a negative report can be issued. The policy in many laboratories is to incubate for the full two days before opening the sealed containers.",
"   </p>",
"   <p>",
"    Direct plating on solid media is adequate for the culture of diarrheal stools, because campylobacters are present in large numbers. However, enrichment culture in a selective broth is recommended when the stool is not fresh or for formed stools from suspected carriers. Enrichment culture is essential for food and environmental samples, which may also require special pretreatment to correct for \"cold shock\" or other bacterial injury; this requires a laboratory with special expertise.",
"   </p>",
"   <p>",
"    The identification of Campylobacter colonies is simple. The bacteria have a characteristic appearance under the microscope, which, together with analysis for oxidase and catalase production, is all that is needed for diagnosis. From a clinical standpoint, it is not necessary to speciate the bacteria into C. jejuni or C. coli, since the diseases they cause are indistinguishable; in most regions, 90 to 95 percent of infections are due to C. jejuni [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/10\">",
"     10",
"    </a>",
"    ]. However, there are occasions when speciation and strain typing are required for epidemiologic purposes.",
"   </p>",
"   <p>",
"    Strain typing is a task best performed at specialized reference laboratories. Serologic typing is the most widely used method. Two systems are in general use: the Penner scheme based upon heat-stable lipopolysaccharide 'O' antigens (over 90 serogroups); and the Lior scheme based upon heat-labile surface protein antigens (112 serogroups) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/11\">",
"     11",
"    </a>",
"    ]. The use of a limited set of antisera from each scheme gives good discrimination, which can be enhanced by the addition of biotyping",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phage typing.",
"   </p>",
"   <p>",
"    Genotyping methods (eg, ribotyping), are capable of excellent discrimination, but are not standardized and none are universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/12\">",
"     12",
"    </a>",
"    ]. Other methods for the direct detection of Campylobacter in clinical specimens, such as DNA probes and amplification by polymerase chain reaction (PCR), have been successful in research studies, but are not yet available in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The whole genome sequences for eight Campylobacter species have been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial and host factors responsible for the pathogenesis of and susceptibility to Campylobacter infection are just beginning to be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors contribute to the ability of Campylobacter to produce illness including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Number of organisms ingested",
"     </li>",
"     <li>",
"      Virulence of the infecting strain",
"     </li>",
"     <li>",
"      Host immunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volunteer studies established that the infective dose could be as low as 500 bacteria, although, a higher dose (9000 bacteria) was needed to produce illness in 50 percent of the subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Campylobacters are sensitive to stomach acidity; as a result, underlying conditions or medications that reduce or buffer gastric acidity predispose to infection. Patients who use proton pump inhibitors are more susceptible to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The dilution and washing action of water and the buffering action of milk might well explain the inordinate size of some waterborne and milk borne outbreaks of Campylobacter enteritis (see below).",
"   </p>",
"   <p>",
"    The mechanisms by which campylobacters are able to attach and invade the intestinal epithelium are complex and are facilitated by the presence of flagella, high molecular weight plasmids, superficial adhesins, and chemotactic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/17,20-27\">",
"     17,20-27",
"    </a>",
"    ]. Campylobacter possess fimbriae-like filaments that enable the organism to attach to intestinal epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/28\">",
"     28",
"    </a>",
"    ]. The bacteria's flagellae promote the motility and chemotaxis needed for C. jejuni to colonize the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The flagellar export apparatus is involved in the secretion of a number of proteins that affect invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/29\">",
"     29",
"    </a>",
"    ]. Intact flagellar synthesis genes are required for maximal C. jejuni invasiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A high-molecular-weight plasmid also enhances the invasive capabilities of C. jejuni virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/23,32\">",
"     23,32",
"    </a>",
"    ]. The plasmid, pVir, has been identified in some clinical Campylobacter isolates and was significantly associated with bloody stools [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/33\">",
"     33",
"    </a>",
"    ]. C. jejuni may adhere to epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/34\">",
"     34",
"    </a>",
"    ], which favors gut colonization. Following attachment, several other bacterial surface proteins (eg, PEB1, CadF) help the organisms to colonize and then invade the intestinal epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/28\">",
"     28",
"    </a>",
"    ]. Other important adhesins include JIpA, a surface exposed lipoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/35\">",
"     35",
"    </a>",
"    ], and CadF, which mediates adhesion by binding to fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low-level production of enterotoxin has been observed in vitro, but production cannot be demonstrated in vivo and the enterotoxin does not appear to play a role in the pathogenesis of Campylobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/27,37\">",
"     27,37",
"    </a>",
"    ]. All C. jejuni isolates possess a gene coding for cytolethal distending toxin that may affect cell cycle kinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; however, not all isolates produce this toxin and its role in disease is not known. Some have postulated that this toxin may play a role in suppressing innate immunity by inducing death of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Course of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an incubation period of about three days (range one to seven days), infection is established in the jejunum, ileum, and often the colon and rectum. A higher inoculum of bacteria is typically associated with a shorter incubation period and more severe illness. The histologic picture is that of acute mucosal inflammation with edema, cellular infiltration of the lamina propria, and crypt abscess formation. These findings are indistinguishable from those seen in salmonellosis and shigellosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Host immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humoral immune mechanisms likely play an important role in protection against infection with Campylobacter. Serum antibodies (eg, IgA, IgG, and IgM) peak two to four weeks postinfection and then decline [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/42\">",
"     42",
"    </a>",
"    ]. Further support for the importance of a humoral immune mechanism in containing campylobacter infection is the observation that patients with hypogammaglobulinemia experience particularly severe and prolonged Campylobacter infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/43\">",
"     43",
"    </a>",
"    ]. The role of cellular immune mechanisms in containing Campylobacter infections is unclear. However, the observation that HIV-infected persons have more severe and persistent disease, and develop extraintestinal Campylobacter infections, suggest that cell-mediated immunity may confer some protection against these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter enteritis is a leading cause of acute diarrhea worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacters are found worldwide, including arctic, temperate, and tropical climates. In 1996, the Centers for Disease Control and Prevention (CDC) and the Emerging Infections Program Foodborne Active Surveillance Network (FoodNet) began collecting data on nine foodborne illnesses in selected areas. In the first year of surveillance, Campylobacter infections were detected more frequently than any other organism, indeed, more than Salmonella and Shigella infections combined. However, from 1996 to 2005, the incidence of Campylobacter infections declined so much that Salmonella infections currently outnumber those caused by Campylobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/46\">",
"     46",
"    </a>",
"    ]. The decline in the incidence of Campylobacter infections is thought to be due to efforts to reduce Campylobacter contamination of poultry and to educate consumers about safe food handling practices. However, considerable variation in the incidence of Campylobacter infections exists between states; for example, the infection rate in California is triple that in Tennessee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Burden of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deaths due to Campylobacter infection are rare in the United States, estimates are that 50 to 150 deaths annually, are at least in part, attributable to Campylobacter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/10\">",
"     10",
"    </a>",
"    ]. The total cost of health care and lost productivity for Campylobacter enteritis in the United States is estimated at $1.5 to $8.0 billion annually [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Demography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age distribution of Campylobacter enteritis in industrialized countries is different from that of other enteric infections. Like most other infections, there is a high incidence in early childhood but, unlike others, there is a pronounced secondary peak in young adults (",
"    <a class=\"graphic graphic_figure graphicRef56850 \" href=\"UTD.htm?11/58/12206\">",
"     figure 1",
"    </a>",
"    ) with a mild male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/10,48\">",
"     10,48",
"    </a>",
"    ]. The reasons for this peak are unknown. Adults tend to be more severely affected than children, while infants usually tolerate the infection well.",
"   </p>",
"   <p>",
"    A different pattern is seen in developing countries where infection is hyperendemic. High transmission rates mean that children become repeatedly infected early in life. Initial infections are often associated with diarrhea, but as immunity is gained, subsequent infections are increasingly likely to be asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Thus, the disease is virtually unknown in older children and adults. In one series of children from Bangladesh and Thailand, IgG antibodies to surface protein antigens of C. jejuni rose early in childhood and then gradually fell; in comparison, IgA antibodies increased progressively through childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In temperate zones, Campylobacter enteritis has a remarkably constant seasonal pattern characterized by a sharp rise of incidence in early summer, a peak in midsummer, and then a steady decline to base levels in winter (",
"    <a class=\"graphic graphic_figure graphicRef77639 \" href=\"UTD.htm?39/50/40749\">",
"     figure 2",
"    </a>",
"    ). A slight secondary peak is sometimes evident in late fall. The reasons for this seasonal pattern are unknown. The seasonal variations in the incidence of Campylobacter infection are not observed in tropical climates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sources and transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. jejuni and C. coli are carried by a wide variety of wild and domestic animals, notably birds [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/51\">",
"     51",
"    </a>",
"    ]; C. coli is particularly associated with pigs. The bacteria are shed widely and can be found in almost any natural water, fresh or saline, in which they can survive for many weeks at temperatures below 15&ordm;C. Water can be a direct source of human infection, though food contamination from food-producing animals is a more significant problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any raw meat can be contaminated with campylobacters. It is almost impossible to prevent contamination of carcasses from gut contents at slaughter. With large animals (eg, cattle, sheep, pigs), the use of air-blast chilling causes surface drying and substantially reduces the number of organisms. Thus, red meats, except offal, are seldom heavily contaminated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contamination of poultry occurs more frequently. Broiler chicken flocks can become heavily colonized, and the bacteria are spread liberally when the carcasses undergo mass processing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/55\">",
"     55",
"    </a>",
"    ]. As a result, approximately 60 percent of retail broiler carcasses and their juices are contaminated with campylobacters, often with counts as high as 10(6) to 10(7) per chicken [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/56\">",
"     56",
"    </a>",
"    ]. According to one study approximately 48 percent of Campylobacter infections are attributable to transmission via poultry [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. Chickens are also a major source of quinolone-resistant Campylobacter infections, an effect that is related to quinolone use in poultry feeds in both the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, infection is acquired from meat in one of two ways: consumption of raw or undercooked meat, or eating food that has become cross contaminated from raw meat [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/63\">",
"     63",
"    </a>",
"    ]. A typical example of cross contamination would be the cutting up of bread or salad on an unwashed board that had just been used to handle raw chicken.",
"   </p>",
"   <p>",
"    In a substantial proportion of Campylobacter cases the source of infection is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/57,64\">",
"     57,64",
"    </a>",
"    ]. One survey of 218 human cases identified the following sources [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chicken consumption &mdash; 48 percent",
"     </li>",
"     <li>",
"      Travel to underdeveloped countries &mdash; 9 percent",
"     </li>",
"     <li>",
"      Drinking non-home well or surface water &mdash; 8 percent",
"     </li>",
"     <li>",
"      Exposure to an animal with diarrhea &mdash; 6 percent",
"     </li>",
"     <li>",
"      Drinking raw milk &mdash; 5 percent",
"     </li>",
"     <li>",
"      Unknown &mdash; 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In industrialized countries, most cases of Campylobacter enteritis are sporadic or part of small family outbreaks. Community outbreaks are uncommon, probably because campylobacters are unable to multiply in food like Salmonellae. Important exceptions are outbreaks caused by the distribution of contaminated water or milk, which have infected as many as 3000 people at a time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. The following findings are noted in outbreaks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In waterborne outbreaks, the water has been unchlorinated or there has been a fault in the chlorination or distribution system [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/65-67,70\">",
"       65-67,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In milk borne outbreaks, the consumed milk has been raw or there has been a failure in the pasteurization process [",
"      <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/68,69,71\">",
"       68,69,71",
"      </a>",
"      ]. It is almost impossible to prevent milk becoming fecally contaminated even in the best run milking parlors. As a result, compulsory pasteurization of all milk sold to the public is the only remedy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection can also be acquired directly from animals or their carcasses. Direct transmission of this sort is usually occupational (eg, farmers, slaughterhouse workers, poultry processors), but domestic infection can also arise from contact with a pet, usually a puppy or kitten with Campylobacter diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5065/abstract/64,72\">",
"     64,72",
"    </a>",
"    ]. Person-to-person infectivity is generally low, although caretakers for children in diapers or incontinent individuals are at risk for transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most Campylobacter infections are transmitted by preparing and consuming chicken, control of Campylobacter infections in broiler flocks is an important first step in reducing the incidence of this infection in humans. Methods used in mass processing and distribution of chicken may amplify the bacterial load. Strategies that have been suggested to reduce such amplification include improvement in chicken house hygiene and water supplies, flock vaccination, and competitive exclusion regimens feeding normal flora to chicks. Efforts to reduce cross-contamination during mass mechanized processing of broiler carcasses may also prove to be helpful in reducing poultry contamination with Campylobacter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Food handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with the employment of the best agricultural practices, it is unlikely that elimination of Campylobacter contamination of poultry will be achieved. The near universal contamination of poultry and the heavy bacterial burden makes such elimination impractical, if not impossible. Therefore, careful food handling practices in the kitchen should be directed towards reducing the risk of transmission to humans. Because C. jejuni is killed by heat, all meat, especially chicken, should be cooked to proper temperature (breasts to 170&ordm;F, thighs to 180&ordm;F). In addition to thorough cooking, care should be taken to avoid cross-contamination: cutting boards, knives, and other utensils used to prepare chicken should be thoroughly washed with hot, soapy water before being used to prepare salads or other foods eaten raw. Irradiation of food will kill Campylobacter as well as other pathogens, but is not yet acceptable to the public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Animal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct transmission from animals may also be prevented by simple hygienic measures of which hand washing is by far the most important; this is particularly relevant to school children and students on farm visits and to families with pets (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Person-to-person transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although person-to-person transmission of Campylobacter infection is unusual, all persons (and especially those who have diarrhea), should wash their hands after using the bathroom. Persons with diarrhea should avoid preparing and handling food until their illness resolves. To date, there have been no reports of transmission of Campylobacter infection by asymptomatic excretors. Asymptomatically infected food handlers or hospital workers need not be excluded from work. However, the importance of hand washing should be emphasized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Water and milk borne transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provision of purified water and the pasteurization (or other heat treatment) of all milk sold to the public are highly effective basic measures that prevent transmission of intestinal pathogens. Pregnant women, the elderly, and persons who are immunocompromised should take particular care to avoid unpasteurized dairy products. Travelers to developing countries and campers should be cautioned against drinking untreated water. Antibiotics are not routinely recommended for prophylaxis against diarrhea in travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"       \"Patient information: Campylobacter infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Campylobacter enteritis is a leading cause of acute diarrhea worldwide. Many Campylobacter spp (\"atypical\" Campylobacters) are recognized to cause human disease; however, the most important species are Campylobacter jejuni and Campylobacter coli. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Campylobacter species'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volunteer studies have established that the infective dose of Campylobacter can be as low as 500 bacteria. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bacterial factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In temperate zones, Campylobacter enteritis has a constant seasonal pattern characterized by a sharp rise of incidence in early summer, a peak in midsummer, and then a steady decline to base levels in winter. The seasonal variations are not observed in tropical climates. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Demography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. jejuni and C. coli are carried by a wide variety of wild and domestic animals, notably birds. The bacteria are shed widely and can be found in almost any natural water, in which they can survive for many weeks at temperatures below 15&ordm;C. Although water can be a direct source of human infection, it is the contamination by campylobacters of the food chain from food-producing animals that is the greater problem. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sources and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any raw meat is likely to be contaminated with campylobacters as it is almost impossible to prevent contamination of carcasses from gut contents at slaughter. Approximately 60 percent of retail broiler carcasses and their juices are contaminated with campylobacters. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sources and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two ways infection is acquired from meats: eating raw or undercooked meat and eating uncooked or previously cooked food that has become cross contaminated from raw meat. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sources and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In industrialized countries, most cases of Campylobacter enteritis are sporadic or part of small family outbreaks. An important exception is community outbreaks caused by the distribution of contaminated water or milk. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sources and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because most Campylobacter infections are transmitted by preparing and consuming chicken, control of Campylobacter infections in broiler flocks and care to prevent cross contamination during food handling are the most effective means to prevent transmission. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Food handling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     MacFadyean F, Stockman S. Report of the department committee appointed by the board of agriculture and fisheries to inquire into epizoonotic abortion, Vol 3. London HMSO. Abstract 1909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/2\">",
"      Vinzent R, Dumas J, Picard N. Septicemie grave au cours de la grossesse due a un vibrion: avortement consectuvie. Bull Acad Nat'l Med 1947; 131:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/3\">",
"      Vernon M, Chatlain R. Taxonomic study of the genus Campylobacter and designation of the neotype strain for the type species. Int J Syst Bacteriol 1973; 23:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/4\">",
"      Vandamme P, Falsen E, Rossau R, et al. Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov. Int J Syst Bacteriol 1991; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/5\">",
"      Moran AP, Upton ME. Factors affecting production of coccoid forms by Campylobacter jejuni on solid media during incubation. J Appl Bacteriol 1987; 62:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/6\">",
"      Rollins DM, Colwell RR. Viable but nonculturable stage of Campylobacter jejuni and its role in survival in the natural aquatic environment. Appl Environ Microbiol 1986; 52:531.",
"     </a>",
"    </li>",
"    <li>",
"     Lastovica AJ, Skirrow MB. Clinical significance of Campylobacter and related species other than Campylobacter jejuni and C. coli. In: Campylobacter, 2nd Ed, Nachamkin I, Blaser MJ (Eds), ASM Press, Washington, DC 2000. p.89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/8\">",
"      Paisley JW, Mirrett S, Lauer BA, et al. Dark-field microscopy of human feces for presumptive diagnosis of Campylobacter fetus subsp. jejuni enteritis. J Clin Microbiol 1982; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/9\">",
"      Blaser MJ, Berkowitz ID, LaForce FM, et al. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med 1979; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman CR, Neimann J, Wegener HC, Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Campylobacter, 2nd Ed, Nachamkin I, Blaser MJ (Eds), ASM Press, Washington, DC 2000. p.121.",
"    </li>",
"    <li>",
"     Nachamkin I. Campylobacter, Heliobacter and related spiral bacteria. In: Manual of Clinical Microbiology, 6th Ed, ASM Press, Washington, DC  p.402.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/12\">",
"      Wassenaar TM, Newell DG. Genotyping of Campylobacter spp. Appl Environ Microbiol 2000; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/13\">",
"      van Camp G, Fierens H, Vandamme P, et al. Identification of enteropathogenic Campylobacter species by oligonucleotide probes and polymerase chain reaction based on 16S rRNA genes. Syst Appl Microbiol 1993; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/14\">",
"      Kulkarni SP, Lever S, Logan JM, et al. Detection of campylobacter species: a comparison of culture and polymerase chain reaction based methods. J Clin Pathol 2002; 55:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/15\">",
"      Poly F, Guerry P. Pathogenesis of Campylobacter. Curr Opin Gastroenterol 2008; 24:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/16\">",
"      Robinson DA. Infective dose of Campylobacter jejuni in milk. Br Med J (Clin Res Ed) 1981; 282:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/17\">",
"      Black RE, Levine MM, Clements ML, et al. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988; 157:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/18\">",
"      Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008; 136:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/19\">",
"      Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/20\">",
"      Caldwell MB, Guerry P, Lee EC, et al. Reversible expression of flagella in Campylobacter jejuni. Infect Immun 1985; 50:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/21\">",
"      Grant CC, Konkel ME, Cieplak W Jr, Tompkins LS. Role of flagella in adherence, internalization, and translocation of Campylobacter jejuni in nonpolarized and polarized epithelial cell cultures. Infect Immun 1993; 61:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/22\">",
"      Yao R, Burr DH, Doig P, et al. Isolation of motile and non-motile insertional mutants of Campylobacter jejuni: the role of motility in adherence and invasion of eukaryotic cells. Mol Microbiol 1994; 14:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/23\">",
"      Bacon DJ, Alm RA, Burr DH, et al. Involvement of a plasmid in virulence of Campylobacter jejuni 81-176. Infect Immun 2000; 68:4384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/24\">",
"      Pei Z, Burucoa C, Grignon B, et al. Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with epithelial cells and intestinal colonization of mice. Infect Immun 1998; 66:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/25\">",
"      Yao R, Burr DH, Guerry P. CheY-mediated modulation of Campylobacter jejuni virulence. Mol Microbiol 1997; 23:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/26\">",
"      Dolg P, Yao R, Burr DH, et al. An environmentally regulated pilus-like appendage involved in Campylobacter pathogenesis. Mol Microbiol 1996; 20:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/27\">",
"      Wassenaar TM, Blaser MJ. Pathophysiology of Campylobacter jejuni infections of humans. Microbes Infect 1999; 1:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/28\">",
"      Gaynor EC, Ghori N, Falkow S. Bile-induced 'pili' in Campylobacter jejuni are bacteria-independent artifacts of the culture medium. Mol Microbiol 2001; 39:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/29\">",
"      Konkel ME, Klena JD, Rivera-Amill V, et al. Secretion of virulence proteins from Campylobacter jejuni is dependent on a functional flagellar export apparatus. J Bacteriol 2004; 186:3296.",
"     </a>",
"    </li>",
"    <li>",
"     Rivera-Amill V, Konkel ME. Secretion of Campylobacter jejuni Cia proteins is contact dependent. In: Mechanisms in the Pathogenesis of Enteric Diseases 2, Paul PS, Francis DH (Eds), Plenum, New York 1999. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/31\">",
"      Konkel ME, Kim BJ, Rivera-Amill V, Garvis SG. Bacterial secreted proteins are required for the internaliztion of Campylobacter jejuni into cultured mammalian cells. Mol Microbiol 1999; 32:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/32\">",
"      Bacon DJ, Alm RA, Hu L, et al. DNA sequence and mutational analyses of the pVir plasmid of Campylobacter jejuni 81-176. Infect Immun 2002; 70:6242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/33\">",
"      Tracz DM, Keelan M, Ahmed-Bentley J, et al. pVir and bloody diarrhea in Campylobacter jejuni enteritis. Emerg Infect Dis 2005; 11:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/34\">",
"      Fauchere JL, Rosenau A, Veron M, et al. Association with HeLa cells of Campylobacter jejuni and Campylobacter coli isolated from human feces. Infect Immun 1986; 54:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/35\">",
"      Jin S, Song YC, Emili A, et al. JlpA of Campylobacter jejuni interacts with surface-exposed heat shock protein 90alpha and triggers signalling pathways leading to the activation of NF-kappaB and p38 MAP kinase in epithelial cells. Cell Microbiol 2003; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/36\">",
"      Konkel ME, Garvis SG, Tipton SL, et al. Identification and molecular cloning of a gene encoding a fibronectin-binding protein (CadF) from Campylobacter jejuni. Mol Microbiol 1997; 24:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/37\">",
"      Wassenaar TM. Toxin production by Campylobacter spp. Clin Microbiol Rev 1997; 10:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/38\">",
"      Whitehouse CA, Balbo PB, Pesci EC, et al. Campylobacter jejuni cytolethal distending toxin causes a G2-phase cell cycle block. Infect Immun 1998; 66:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/39\">",
"      Pickett CL, Pesci EC, Cottle DL, et al. Prevalence of cytolethal distending toxin production in Campylobacter jejuni and relatedness of Campylobacter sp. cdtB gene. Infect Immun 1996; 64:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/40\">",
"      Hickey TE, Majam G, Guerry P. Intracellular survival of Campylobacter jejuni in human monocytic cells and induction of apoptotic death by cytholethal distending toxin. Infect Immun 2005; 73:5194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/41\">",
"      Shenker BJ, Besack D, McKay T, et al. Induction of cell cycle arrest in lymphocytes by Actinobacillus actinomycetemcomitans cytolethal distending toxin requires three subunits for maximum activity. J Immunol 2005; 174:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/42\">",
"      Blaser MJ, Duncan DJ. Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay. Infect Immun 1984; 44:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/43\">",
"      Melamed I, Bujanover Y, Igra YS, et al. Campylobacter enteritis in normal and immunodeficient children. Am J Dis Child 1983; 137:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/44\">",
"      Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir Immune Defic Syndr 1991; 4:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/45\">",
"      Tee W, Mijch A. Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review. Clin Infect Dis 1998; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 States, United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/47\">",
"      Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barr&eacute; syndrome. J Infect Dis 1997; 176 Suppl 2:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/48\">",
"      Skirrow MB. A demographic survey of campylobacter, salmonella and shigella infections in England. A Public Health Laboratory Service Survey. Epidemiol Infect 1987; 99:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/49\">",
"      Blaser MJ, Taylor DN, Echeverria P. Immune response to Campylobacter jejuni in a rural community in Thailand. J Infect Dis 1986; 153:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/50\">",
"      Calva JJ, Ruiz-Palacios GM, Lopez-Vidal AB, et al. Cohort study of intestinal infection with campylobacter in Mexican children. Lancet 1988; 1:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/51\">",
"      Gardner TJ, Fitzgerald C, Xavier C, et al. Outbreak of campylobacteriosis associated with consumption of raw peas. Clin Infect Dis 2011; 53:26.",
"     </a>",
"    </li>",
"    <li>",
"     Jacobs-Reitsma W. Campylobacter in the food supply. In: Campylobacter, 2nd Ed, Nachamkin I, Blaser MJ (Eds), ASM Press, Washington, DC 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/53\">",
"      Stern NJ, Hernandez MP, Blankenship L, et al. Prevalence and distribution of Campylobacter jejuni and Campylobacter coli in retail meats. J Food Protect 1985; 48:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/54\">",
"      Bolton FJ, Dawkins HC, Hutchinson DN. Biotypes and serotypes of thermophilic campylobacters isolated from cattle, sheep and pig offal and other red meats. J Hyg (Lond) 1985; 95:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/55\">",
"      Jones FT, Axtell RC, Rives DV, et al. A survey of Campylobacter jejuni contamination in modern broiler production and processing systems. J Food Protect 1991; 54:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/56\">",
"      Hood AM, Pearson AD, Shahamat M. The extent of surface contamination of retailed chickens with Campylobacter jejuni serogroups. Epidemiol Infect 1988; 100:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/57\">",
"      Harris NV, Weiss NS, Nolan CM. The role of poultry and meats in the etiology of Campylobacter jejuni/coli enteritis. Am J Public Health 1986; 76:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/58\">",
"      Neal KR, Slack RC. The autumn peak in campylobacter gastro-enteritis. Are the risk factors the same for travel- and UK-acquired campylobacter infections? J Public Health Med 1995; 17:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/59\">",
"      Denno DM, Keene WE, Hutter CM, et al. Tri-county comprehensive assessment of risk factors for sporadic reportable bacterial enteric infection in children. J Infect Dis 2009; 199:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/60\">",
"      Danis K, Di Renzi M, O'Neill W, et al. Risk factors for sporadic Campylobacter infection: an all-Ireland case-control study. Euro Surveill 2009; 14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/61\">",
"      Stafford RJ, Schluter PJ, Wilson AJ, et al. Population-attributable risk estimates for risk factors associated with Campylobacter infection, australia. Emerg Infect Dis 2008; 14:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/62\">",
"      Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999; 340:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/63\">",
"      Brown P, Kidd D, Riordan T, Barrell RA. An outbreak of food-borne Campylobacter jejuni infection and the possible role of cross-contamination. J Infect 1988; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/64\">",
"      Saeed AM, Harris NV, DiGiacomo RF. The role of exposure to animals in the etiology of Campylobacter jejuni/coli enteritis. Am J Epidemiol 1993; 137:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/65\">",
"      Vogt RL, Sours HE, Barrett T, et al. Campylobacter enteritis associated with contaminated water. Ann Intern Med 1982; 96:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/66\">",
"      Mentzing LO. Waterborne outbreaks of campylobacter enteritis in central Sweden. Lancet 1981; 2:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/67\">",
"      Sacks JJ, Lieb S, Baldy LM, et al. Epidemic campylobacteriosis associated with a community water supply. Am J Public Health 1986; 76:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/68\">",
"      Robinson DA, Jones DM. Milk-borne campylobacter infection. Br Med J (Clin Res Ed) 1981; 282:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/69\">",
"      Wood RC, MacDonald KL, Osterholm MT. Campylobacter enteritis outbreaks associated with drinking raw milk during youth activities. A 10-year review of outbreaks in the United States. JAMA 1992; 268:3228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/70\">",
"      Richardson G, Thomas DR, Smith RM, et al. A community outbreak of Campylobacter jejuni infection from a chlorinated public water supply. Epidemiol Infect 2007; 135:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Campylobacter jejuni infection associated with unpasteurized milk and cheese--Kansas, 2007. MMWR Morb Mortal Wkly Rep 2009; 57:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5065/abstract/72\">",
"      Fullerton KE, Ingram LA, Jones TF, et al. Sporadic campylobacter infection in infants: a population-based surveillance case-control study. Pediatr Infect Dis J 2007; 26:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2707 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5065=[""].join("\n");
var outline_f4_60_5065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Campylobacter species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Detection in the laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Course of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Host immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Burden of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Demography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sources and transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Food handling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Animal transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Person-to-person transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Water and milk borne transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2707\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2707|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/58/12206\" title=\"figure 1\">",
"      Epidemiology of Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/50/40749\" title=\"figure 2\">",
"      Seasonal pattern Campy infxn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2707|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/28/20929\" title=\"picture 1\">",
"      Campylobacter morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/34/14895\" title=\"picture 2\">",
"      Gram stain of Campylobacter jejuni in stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35518\" title=\"picture 3\">",
"      Campylobacter jejuni colonies on CAMPY agar",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19368?source=related_link\">",
"      Infection with less common Campylobacter species and related bacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=related_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5066="What's new in pediatrics";
var content_f4_60_5066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in pediatrics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/60/5066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5066/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5066/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5066/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/60/5066/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/60/5066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     GENERAL PEDIATRICS AND ADOLESCENT MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Antibiotics for children with uncomplicated severe acute malnutrition",
"    </span>",
"   </p>",
"   <p>",
"    For children&nbsp;with uncomplicated severe acute malnutrition&nbsp;treated in an outpatient setting, we recommend&nbsp;a brief empiric course of oral antibiotics (eg, amoxicillin or cefdinir for seven days). This practice&nbsp;is now supported by a prospective randomized trial in&nbsp;which children were&nbsp;treated with a seven-day course of amoxicillin, cefdinir, or placebo in addition to nutritional rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/1\">",
"     1",
"    </a>",
"    ]. Either amoxicillin or cefdinir improved recovery rates, time to recovery, and weight gain as compared to placebo, and also reduced mortality.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=see_link&amp;anchor=H28885677#H28885677\">",
"     \"Severe malnutrition in children in developing countries: Treatment\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention of anterior cruciate ligament (ACL) injury",
"    </span>",
"   </p>",
"   <p>",
"    ACL rupture is&nbsp;a&nbsp;severe and increasingly common&nbsp;injury among female athletes.&nbsp;Although well designed prevention programs have been shown to reduce ACL injury rates, guidelines are not clear about the age at which to introduce such programs.&nbsp;According to a meta-analysis of 14 randomized trials, females in early adolescence, or possibly even preadolescence, may benefit the most from neuromuscular training prevention programs.&nbsp;In this meta-analysis, females in their mid-teens had greater reductions in their rate of ACL injury&nbsp;than females in their late teens&nbsp;or early adulthood&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/2\">",
"     2",
"    </a>",
"    ]. These results suggest that it is important to implement prevention programs before female athletes develop poor mechanics&nbsp;for movements associated with an increased risk of ACL injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link&amp;anchor=H25#H25\">",
"     \"Anterior cruciate ligament injury\", section on 'Neuromuscular training'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bracing for pectus carinatum",
"    </span>",
"   </p>",
"   <p>",
"    Self-adjustable chest braces are available for correction of pectus carinatum, as an alternative to surgical correction. Bracing protocols appear to be challenging to complete, but among those patients who do, the success rate may be as high as 75 to 90 percent. The efficacy of bracing is associated with the degree of compliance with the bracing protocol, and with initiation of bracing at an earlier pubertal status&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link&amp;anchor=H19#H19\">",
"     \"Pectus carinatum\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     New levonorgestrel-releasing IUD",
"    </span>",
"   </p>",
"   <p>",
"    A lower-dose (13.5 mg) levonorgestrel-releasing intrauterine device (IUD; Skyla) became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/4\">",
"     4",
"    </a>",
"    ]. It is smaller in size than the 52 mg levonorgestrel IUD (Mirena)&nbsp;and thus may be easier to insert in nulliparous women. Because of the lower levonorgestrel dose, it is approved for up to three years of use (the 52 mg dose is approved for up to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     \"Levonorgestrel: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute kidney injury after synthetic cannabinoid use",
"    </span>",
"   </p>",
"   <p>",
"    Synthetic cannabinoids, including tetrahydrocannabinol [THC], cannabidiol [CBD], and cannabinol [CBN], are analogs of naturally-occurring chemicals found in marijuana. In two small case series, synthetic cannabinoid or &ldquo;Spice&rdquo; use has been associated with reversible acute kidney injury necessitating renal replacement therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Pathologically, the injury is characterized by acute tubular necrosis and interstitial nephritis. In some instances, these previously-healthy&nbsp;young adults&nbsp;reported smoking a blueberry- or bubblegum-flavored synthetic cannabinoid. A unique synthetic cannabinoid, 1-((5-fluoropentyl)-1H-indol-3yl) (2,23,3,-tetramethylcyclopropyl) methanone (also called XLR-11) was found in clinical specimens and product samples [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the specific chemical agent responsible for causing renal toxicity is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H1913412#H1913412\">",
"     \"Designer drugs of abuse\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intraoperative glucocorticoids and tonsillectomy",
"    </span>",
"   </p>",
"   <p>",
"    Intravenous dexamethasone is frequently administered after induction of anesthesia to prevent postoperative nausea and vomiting in children undergoing tonsillectomy. Three recent meta-analyses found no significant difference in the pooled relative risk of any postoperative bleeding between patients receiving dexamethasone and placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], although the risk of more severe hemorrhage requiring operative reintervention was higher in the dexamethasone group in one analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/10\">",
"     10",
"    </a>",
"    ]. A randomized trial published subsequent to these meta-analyses found no difference between the dexamethasone and placebo groups in the rates of significant postoperative hemorrhage, although a slightly higher rate of mild, self- or parent-reported postoperative bleeding was seen in the dexamethasone-treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/11\">",
"     11",
"    </a>",
"    ]. The small number of events in the trial limits the ability to draw firm conclusions and further investigation is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link&amp;anchor=H11436020#H11436020\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Intraoperative glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Suicidal risk in adolescents with psychiatric disorders",
"    </span>",
"   </p>",
"   <p>",
"    The risk of suicide in adolescents with psychiatric disorders depends upon the severity of the illness. As an example, suicidal behavior is increased in patients with psychotic features, such as command auditory hallucinations to commit self-harm. A community-based study found that among two adolescent populations (age 11 to 13 years, n = 78, and age 13 to 15 years, n = 72), suicidal ideation or behavior were more common in adolescents with psychiatric disorders (eg, depressive disorder, anxiety disorder, or attention deficit hyperactivity disorder) plus psychotic symptoms, compared to adolescents with psychiatric disorders but no psychotic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H7#H7\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Psychiatric disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Injuries in children living with an abused child",
"    </span>",
"   </p>",
"   <p>",
"    Children who live with an abused child are also at high risk for child maltreatment. In a prospective, multicenter observational study of household contacts of abused children, at least one abusive fracture on skeletal survey was found in 12 percent of the 134 household contacts who were two years of age or younger [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/13\">",
"     13",
"    </a>",
"    ]. None of the fractures detected by skeletal survey were clinically suspected or had associated physical findings. This study supports the practice of obtaining skeletal surveys, in addition to careful history and physical examination, for all infants and young children who reside with an abused child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H4721692#H4721692\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Identifying injuries in other children at risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vision screening with photoscreening or autorefraction",
"    </span>",
"   </p>",
"   <p>",
"    &shy;Photoscreening uses optical images of the red reflex to detect risk factors for amblyopia (eg, refractive errors, cataracts, and strabismus). Autorefraction uses automated retinoscopy or wave-front technology to evaluate refractive error. Photoscreening and autorefraction can be performed with minimal patient cooperation and may be particularly useful in preverbal, preliterate, or developmentally delayed children. In an updated policy statement, the American Academy of Pediatrics, the American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus, and the American Association of Certified Orthoptists recommend photoscreening or autorefraction as an alternative to visual behavior and visual acuity screening in preschool children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/14\">",
"     14",
"    </a>",
"    ]. The 2002 policy statement indicated that instrument-based screening was promising, but additional study was necessary. Since then, observational studies have confirmed the potential benefit of instrument based screening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H3092026#H3092026\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Photoscreening and autorefraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Obesity and sugar-sweetened beverages",
"    </span>",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that consumption of sugar-sweetened beverages (including fruit juice) is an important contributor to the development of obesity in some populations. A randomized trial demonstrated that reducing consumption of sugar-sweetened beverages among overweight and obese adolescents is associated with a modest decrease in body mass index (BMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/17\">",
"     17",
"    </a>",
"    ]. In a separate randomized trial in children (most of whom were in a healthy weight range), consumption of one serving of an artificially sweetened beverage daily was associated with less weight gain and fat accumulation as compared with consumption of a sugar-sweetened beverage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H19815865#H19815865\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Sugar-sweetened beverages'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Obesity and endocrine-disrupting chemicals",
"    </span>",
"   </p>",
"   <p>",
"    Preliminary evidence suggests the possibility that obesity could be triggered or exacerbated by exposure to environmental endocrine disrupting chemicals, such as bisphenol A (BPA). BPA is a common contaminant of foods sold in cans and plastic packaging. In a large population-based study in children, higher concentrations of BPA in the urine were associated with an increased prevalence of obesity (10.3 percent obesity in the lowest quartile of BPA, versus 22.3 percent obesity in the highest quartile of BPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/19\">",
"     19",
"    </a>",
"    ]. It is possible that the observed association is due to dietary or environmental variables that were not included in the analysis, or by increased storage of BPA in adipose tissue among obese individuals, rather than a direct causal effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H5397879#H5397879\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Toxins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEONATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Updated policy statement for retinopathy of prematurity",
"    </span>",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Section on Ophthalmology, the American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus, and the American Association of Certified Orthoptists updated their policy statement on retinopathy of prematurity (ROP) in January 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/20\">",
"     20",
"    </a>",
"    ]. Important changes include recommendations for treatment of high-risk prethreshold ROP as well as for threshold ROP and more frequent evaluation of infants with suspected aggressive posterior ROP and infants with immature vascularization without ROP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H24#H24\">",
"     \"Retinopathy of prematurity\", section on 'Indications for treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H21#H21\">",
"     \"Retinopathy of prematurity\", section on 'Evaluation schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Respiratory distress syndrome and CPAP",
"    </span>",
"   </p>",
"   <p>",
"    A follow-up report of the SUPPORT trial provided further evidence that the initial use of continuous positive airway pressure (CPAP) is a good alternative to early intubation and surfactant administration for extremely premature infants (gestational age between 24 and 27 weeks), who are at-risk for respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/21\">",
"     21",
"    </a>",
"    ]. At 18 to 22 months corrected age, there was no difference in death or neurodevelopmental outcome between the initial CPAP and intubation with surfactant administration groups (27.9 versus 29.9 percent). Impaired neurodevelopmental outcome was defined as a predefined poor score on cognitive testing, moderate or severe cerebral palsy, hearing impairment, or bilateral visual impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056129#H23056129\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Continuous positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Effect of fresh RBCs transfusion in preterm infants",
"    </span>",
"   </p>",
"   <p>",
"    It has been suggested that the use of fresh red blood cell (RBC) transfusions compared with current standard transfusions would lower rates of organ dysfunction, nosocomial infection, and length of stay in preterm infants. However, a Canadian multicenter trial of premature infants (birth weight less than 1250 g) demonstrated",
"    <strong>",
"     no",
"    </strong>",
"    benefit in the use of fresh RBCs transfusion (mean age of RBCs, 5.1 &plusmn; 2.1 days) compared with transfusions using RBCs stored under current standard blood bank practice (mean age of RBCs, 14.6 &plusmn; 8.3 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/22\">",
"     22",
"    </a>",
"    ]. Specifically, there was no difference between the two groups in the primary composite outcome of major neonatal morbidities that included necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H11#H11\">",
"     \"Red blood cell transfusions in the newborn\", section on 'Packed red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Osteopenia of prematurity and rib fractures",
"    </span>",
"   </p>",
"   <p>",
"    Osteopenia, a common complication of premature birth, is generally not clinically apparent and does not usually present with bone fractures. However, in a retrospective multicenter review of chest radiographs of 1446 premature infants, rib fractures were detected in about 2 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/23\">",
"     23",
"    </a>",
"    ]. Fractures were attributed to osteopenia of prematurity in two-thirds of the cases (17 of 26 patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=see_link&amp;anchor=H12#H12\">",
"     \"Calcium and phosphorus requirements of newborn infants\", section on 'Osteopenia of prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ALLERGY, IMMUNOLOGY, AND RHEUMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Biologic agents for systemic onset juvenile idiopathic arthritis",
"    </span>",
"   </p>",
"   <p>",
"    Glucocorticoids provide rapid onset of action and almost uniform efficacy for severely ill children with systemic onset juvenile idiopathic arthritis (JIA). Thus, historically, most pediatric rheumatologists have used glucocorticoids in these patients, with methotrexate used as a steroid-sparing agent for longer-term control. However, three recent randomized trials have demonstrated that anticytokine biologic agents, such as monoclonal antibodies to interleukin-1 (IL-1) or IL-6, are effective in reducing clinical symptoms in patients with systemic onset JIA refractory to conventional therapy (nonsteroidal antiinflammatory drugs, glucocorticoids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    methotrexate) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. More limited data suggest they are also beneficial when used early in the care of children with severe systemic onset JIA (ie, instead of glucocorticoids) once the diagnosis is confirmed. In addition, most biologic agents (eg, anakinra, canakinumab, tocilizumab) have more favorable side effect profiles than cytotoxic agents (eg, methotrexate) or long-term use of glucocorticoids. Thus, the choice for first-line therapy for refractory disease, and in some cases for initial therapy for severe disease, has shifted to the biologic agents.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=see_link&amp;anchor=H15847723#H15847723\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'Therapy for refractory disease/Initial therapy for severe disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chapel Hill Consensus Conference on nomenclature of vasculitides",
"    </span>",
"   </p>",
"   <p>",
"    Revisions in the commonly used terms for the various vasculitides have been proposed by the 2012 International Chapel Hill Consensus Conference (CHCC) on nomenclature of vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/26\">",
"     26",
"    </a>",
"    ]. The&nbsp;2012 CHCC suggests&nbsp;\"eosinophilic granulomatosis with polyangiitis (Churg-Strauss),\" abbreviated EGPA, in place of Churg-Strauss syndrome, and formal adoption of \"antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)\" for the group&nbsp;of disorders&nbsp;that includes&nbsp;microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and EGPA. Some of the other changes suggested by the 2012 CHCC included \"immunoglobulin A (IgA) vasculitis (Henoch-Sch&ouml;nlein)\" in lieu of Henoch-Sch&ouml;nlein purpura, further definition of hypocomplementemic urticarial vasculitis (HUV) as \"HUV (anti-C1q vasculitis),\" and \"cryoglobulinemic vasculitis\" in place of essential cryoglobulinemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CARDIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Safety of competitive athletic participation in patients with LQTS",
"    </span>",
"   </p>",
"   <p>",
"    The long QT syndrome (LQTS), a genetic disorder whose phenotypic expression is a prolonged corrected QT interval on the electrocardiogram (ECG), has been associated with a significant risk for ventricular arrhythmias and sudden cardiac death (SCD). As of 2005, both European and American professional societies have recommended significant restrictions in activity in patients with LQTS to reduce the risk of ventricular arrhythmias and SCD. However, among 130 patients (out of a total cohort of 353 patients) with LQTS who remained active in competitive athletics and were followed for an average of 5.5 years, there were no cardiac events among 70 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    negative patients (ie, QT interval within the normal range)&nbsp;and only one arrhythmic event among 60 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/27\">",
"     27",
"    </a>",
"    ]. While our experts continue to recommend restricted athletic participation in accordance with the Bethesda Conference recommendations, these cohort data are reassuring that continued athletic participation in patients with genotype positive LQTS is relatively safe.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H28#H28\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Congenital long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DERMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Proactive, intermittent therapy for long-term control of atopic dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    The long-term control of skin inflammation is a major challenge in the management of patients with atopic dermatitis. The 2012 European and American guidelines&nbsp;for the treatment of atopic dermatitis recommend proactive, intermittent topical&nbsp;therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. After induction of remission with continuous topical therapy, twice weekly&nbsp;application of topical&nbsp;corticosteroids&nbsp;to eczema-prone areas may prevent relapses in both adults and children with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H41442152#H41442152\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Prevention of relapses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Guidelines for propranolol treatment for infantile hemangiomas",
"    </span>",
"   </p>",
"   <p>",
"    Based on multiple observational studies, propranolol has been adopted as a first-line treatment for infantile hemangiomas that have potential to impair vital functions or cause disfigurement and for ulcerated hemangiomas that may cause permanent disfigurement, interfere with daily life activities, or do not respond to wound care measures. Protocols for&nbsp;propranolol use have varied from center to center. In December 2012, a multidisciplinary consensus panel published guidelines for initiation and use of propranolol for infantile hemangiomas&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/30\">",
"     30",
"    </a>",
"    ]. The guidelines include specific recommendations for pretreatment evaluation, contraindications, hospitalization, dose initiation and escalation, and monitoring for adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of infantile hemangiomas\", section on 'Propranolol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Topical ivermectin for pediculosis capitis",
"    </span>",
"   </p>",
"   <p>",
"    The emergence of resistance to treatments for pediculosis capitis (head lice) has fueled the desire to identify additional effective treatments for this condition. In two randomized trials, a single 10-minute application of topical ivermectin was superior to a placebo lotion for the eradication of lice [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/31\">",
"     31",
"    </a>",
"    ]. A combined analysis of the trial results revealed that among the index patients (youngest household member with at least three live lice detected on examination), 131 of 138 (95 percent) treated with topical ivermectin and 46 of 147 (31 percent) treated with the placebo lotion were free of live lice on day two. By day 15, live lice were absent in 74 and 18 percent of patients, respectively. Adverse events were infrequent and occurred at similar rates in both groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H2579574#H2579574\">",
"     \"Pediculosis capitis\", section on 'Topical ivermectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DEVELOPMENT AND BEHAVIORAL PROBLEMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevalence of autism spectrum disorders",
"    </span>",
"   </p>",
"   <p>",
"    In the 2011-2012 National Survey of Children&rsquo;s Health, the prevalence of parent-reported autism spectrum disorder (ASD) among 6- to 17-year-old children in the&nbsp;United States was 1 in 50, an increase from 1 in 86 in&nbsp;2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/32\">",
"     32",
"    </a>",
"    ]. The increase was largely&nbsp;due to&nbsp;newly diagnosed ASD in&nbsp;6-to 13-year-old children,&nbsp;suggesting&nbsp;that&nbsp;the increase&nbsp;is related to improved awareness and ascertainment of ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H9#H9\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EMERGENCY MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Very low risk criteria for pediatric intraabdominal injury",
"    </span>",
"   </p>",
"   <p>",
"    In a&nbsp;multicenter, prospective observational study of&nbsp;over 12,000&nbsp;children with blunt torso trauma, clinical features that predicted a very low risk of intraabominal injury (IAI) requiring intervention (eg, laparotomy, angiographic embolization, blood transfusion, or hospitalization for two nights or longer)&nbsp;were identified&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow coma scale &ge;14",
"     </li>",
"     <li>",
"      No evidence of abdominal wall trauma or seat belt sign",
"     </li>",
"     <li>",
"      No abdominal tenderness",
"     </li>",
"     <li>",
"      No complaints of abdominal pain",
"     </li>",
"     <li>",
"      No vomiting",
"     </li>",
"     <li>",
"      No thoracic wall trauma",
"     </li>",
"     <li>",
"      No decreased breath sounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absolute risk of IAI for the&nbsp;more than 5000&nbsp;children who met all seven of these criteria was 0.1 percent. However, 23 percent of these patients underwent computed tomography (CT)&nbsp;of the abdomen. Thus, implementation of this rule, if validated, has significant potential to reduce the number of abdominal CTs in children.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hot water immersion for jellyfish stings",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review of trials and observational studies found that hot water immersion is more effective for treating pain caused by stings of Physalia species (Man of war) and",
"    <em>",
"     Carybdea alata",
"    </em>",
"    (Hawaiian box jellyfish) than other topical therapies, including cold therapy or application of acetic acid or papain meat tenderizer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/34\">",
"     34",
"    </a>",
"    ]. Hot water immersion may be helpful for stings from other jellyfish as well. However, application of acetic acid to prevent further discharge of venom from adherent nematocysts supersedes hot water immersion in importance for all stings caused by",
"    <em>",
"     Chironex fleckeri",
"    </em>",
"    (Australian box jellyfish) and for life-threatening stings caused by",
"    <em>",
"     C. alata",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43016?source=see_link&amp;anchor=H15#H15\">",
"     \"Jellyfish stings\", section on 'Hot water immersion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43016?source=see_link&amp;anchor=H12735251#H12735251\">",
"     \"Jellyfish stings\", section on 'Acetic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Bottle-feeding and risk for pyloric stenosis",
"    </span>",
"   </p>",
"   <p>",
"    The etiology of infantile hypertrophic pyloric stenosis (IHPS) is multifactorial, involving genetic predisposition and environmental factors (eg, macrolide antibiotics). A large population-based study from Denmark found that bottle-feeding during the first four months of life increased the risk for IHPS more than four-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/35\">",
"     35",
"    </a>",
"    ]. Most of the included subjects used formula for bottle-feeds rather than expressed breast milk, so the study did not determine whether the increased risk is related to the formula or to the mechanism of bottle-feeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link&amp;anchor=H2#H2\">",
"     \"Infantile hypertrophic pyloric stenosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Antibiotic exposure and risk for inflammatory bowel disease",
"    </span>",
"   </p>",
"   <p>",
"    Genetic and environmental factors contribute to the risk of developing inflammatory bowel disease (IBD). A new study suggests that exposure during early childhood to antibiotics that target anaerobic bacteria increases the risk for IBD. This was shown in a large population study from the United Kingdom, in which anti-anaerobic antibiotic exposure increased the relative risk for IBD by 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk was greatest for exposures before one year of age as compared with later in childhood or adolescence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\", section on 'Perinatal and early exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     GENETICS AND PEDIATRIC METABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     New drug for long term treatment of some urea cycle disorders",
"    </span>",
"   </p>",
"   <p>",
"    Oral glycerol phenylbutyrate (Ravicti), an alternative to oral sodium phenylbutyrate,&nbsp;has been&nbsp;approved by the Food and Drug Administration in the US for use in patients greater than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/37\">",
"     37",
"    </a>",
"    ]. Glycerol phenylbutyrate acts as a slow release form of sodium phenylbutyrate, achieving more stable control of ammonia levels over a 24 hour period. In addition, it may offer advantages with regards to tolerability and palatability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=see_link&amp;anchor=H15#H15\">",
"     \"Urea cycle disorders: Management\", section on 'Management of infants after initial stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     HEMATOLOGY AND ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Risk of inhibitor development in patients with hemophilia A",
"    </span>",
"   </p>",
"   <p>",
"    Up to&nbsp;one-third of patients with severe hemophilia A produce antibodies (ie, inhibitors) to infused factor VIII;&nbsp;the incidence of inhibitor development&nbsp;with different products is not well studied. To address product-related factors, over 500 previously untreated children with severe hemophilia A were followed prospectively after receiving the factor VIII product chosen by their physician [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk of inhibitor formation was similar with recombinant and plasma-derived products and was not affected by the amount of von Willebrand factor in the product&nbsp;or by switching products. Second-generation full-length recombinant products had a slightly higher risk of inhibitor development compared with third-generation recombinant products. Other factors such as cost, safety, and purity continue to be important in the choice of factor VIII product. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link&amp;anchor=H15593804#H15593804\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Replacement product'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     INFECTIOUS DISEASES AND IMMUNIZATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Management of asymptomatic neonates exposed to HSV during delivery",
"    </span>",
"   </p>",
"   <p>",
"    The risk of herpes simplex virus (HSV)&nbsp;transmission to neonates&nbsp;during delivery in women with active genital HSV lesions varies from &lt;2 percent for recurrent maternal&nbsp;infection to 25 to 60 percent for primary infection. The increasing availability of HSV serologic tests that distinguish between HSV-1 and HSV-2 permits more accurate characterization of maternal infection (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"UTD.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ), allowing the evaluation and management of asymptomatic neonates exposed to HSV at delivery to be tailored according to risk. In February 2013 the American Academy of Pediatrics published guidelines for the management of asymptomatic neonates born to women with active genital lesions&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/39\">",
"     39",
"    </a>",
"    ].&nbsp;The guidelines recommend that women with active genital lesions at the time of delivery and no history of HSV undergo type-specific HSV serologic testing after delivery (if available). Asymptomatic neonates born to such women should undergo full evaluation for HSV at approximately 24 hours of age and be treated with acyclovir 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously per day divided in three doses. The duration of therapy is determined by the neonate&rsquo;s clinical status, results of the neonate&rsquo;s evaluation for HSV disease, and maternal HSV infection classification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link&amp;anchor=H510233446#H510233446\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'No maternal history of HSV, active lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"    </span>",
"   </p>",
"   <p>",
"    Individuals in several countries in Europe have developed narcolepsy after receiving Pandemrix, an AS03 (oil-in-water emulsion)-adjuvanted 2009 pandemic H1N1 influenza vaccine. Pandemrix was used in certain countries during the 2009-2010 H1N1 influenza pandemic, but it was not used in the United States. This association was first reported among&nbsp;children and adolescents in Finland and Sweden in 2010&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/40\">",
"     40",
"    </a>",
"    ]. These findings have been confirmed in a subsequent large retrospective database review that included six countries in Europe over a 10-year period; increased narcolepsy rates were observed in Sweden, Finland, and Denmark after the initiation of Pandemrix vaccination campaigns, primarily in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/41\">",
"     41",
"    </a>",
"    ].&nbsp;An increased risk of narcolepsy was also observed in children and adolescents who received Pandemrix&nbsp;in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H592844613#H592844613\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Narcolepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     IV acyclovir shortage in the United States",
"    </span>",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of intravenous (IV) acyclovir in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. IV acyclovir, if available, is the drug of choice for the following indications: neonates with proven herpes simplex virus (HSV) disease, pregnant women with HSV or varicella-zoster virus infection, and individuals with herpes simplex encephalitis; during this shortage, IV acyclovir should be reserved for patients with these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/45\">",
"     45",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm#acyclovir\">",
"     web site",
"    </a>",
"    for the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm\">",
"     US Food and Drug Administration",
"    </a>",
"    for information about the availability of IV acyclovir. Treatment recommendations for the use of alternative antiviral agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Combination vaccine for meningococcus and Haemophilus influenzae type b",
"    </span>",
"   </p>",
"   <p>",
"    A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix, HibMenCY) was approved by the US Food and Drug Administration in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In prelicensure trials, this vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations. In January 2013, the United States Advisory Panel on Immunization Practices began recommending HibMenCY for certain infants and toddlers at increased risk for meningococcal disease, beginning at two months of age (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. It is the first meningococcal vaccine to be recommended in the United States for use in infants younger than nine months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H937132#H937132\">",
"     \"Meningococcal vaccines\", section on 'Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"     \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Oseltamivir treatment approved for infants &ge;2 weeks",
"    </span>",
"   </p>",
"   <p>",
"    In December 2012, the US Food and Drug Administration approved oseltamivir for the treatment of influenza in infants &ge;2 weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/50\">",
"     50",
"    </a>",
"    ]. Oseltamivir had previously been approved in the US for treatment of influenza in children &ge;1 year of age. For prophylaxis of influenza in the US, oseltamivir continues to be approved only for infants &ge;1 year of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H5#H5\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Neuraminidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/51\">",
"     51",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     2012-2013 seasonal influenza vaccine effectiveness",
"    </span>",
"   </p>",
"   <p>",
"    In a case-control study conducted early in the 2012-2013 influenza season, the United States Centers for Disease Control and Prevention estimated that the effectiveness of 2012-2013 seasonal influenza vaccine in preventing laboratory-confirmed influenza is approximately 60 percent overall (55 percent for influenza A viruses and 70 percent for influenza B viruses) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/52\">",
"     52",
"    </a>",
"    ]. Given the moderate effectiveness of the vaccine, influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H83326789#H83326789\">",
"     \"Seasonal influenza vaccination in children\", section on 'Effectiveness for 2012-2013 season'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Vertical transmission of hepatitis C",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review of observational studies on risk of mother-to-infant hepatitis C virus (HCV) transmission found no clear association between infection in the infant and mode of delivery or breastfeeding practices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/53\">",
"     53",
"    </a>",
"    ]. Women infected with HCV",
"    <strong>",
"     do not",
"    </strong>",
"    need to be advised to avoid vaginal delivery or breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link&amp;anchor=H68345961#H68345961\">",
"     \"Vertical transmission of hepatitis C virus\", section on 'Mode of delivery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link&amp;anchor=H68346108#H68346108\">",
"     \"Vertical transmission of hepatitis C virus\", section on 'Breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Safety and efficacy of influenza vaccination in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for pregnant women because both mother and fetus are at increased risk of complications related to this infection, including fetal death. In addition, maternal vaccination provides passive protection to the infant. However, concerns about vaccine safety have interfered with compliance in this patient group. The safety and efficacy of vaccination of pregnant women were confirmed in a retrospective analysis of over 100,000 pregnancies during the 2009 influenza A (H1N1) pandemic in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/54\">",
"     54",
"    </a>",
"    ]. Vaccination during pregnancy substantially reduced the risk of a maternal influenza diagnosis (adjusted hazard ratio, 0.30) and was associated with a trend in reduction of fetal death. All women who are pregnant or will be pregnant during influenza season should receive the inactivated influenza vaccine, regardless of pregnancy trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795661#H5795661\">",
"     \"Influenza and pregnancy\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Meningococcal serogroup B vaccine",
"    </span>",
"   </p>",
"   <p>",
"    Although group B meningococcus is one of the most common serotypes causing infection, no broadly effective vaccine preparation is licensed for use to prevent infection with this serogroup [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. A major challenge in the development of a vaccine has been that the serogroup B polysaccharide is a very poor immunogen in humans, probably due to the similarity of its immunochemical structure to human intracellular adhesion molecules. In January 2013, the European Commission approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/57\">",
"     57",
"    </a>",
"    ]. The vaccine includes three recombinant proteins (neisserial adhesin A, factor H binding protein, and neisserial heparin binding antigen) with outer membrane vesicles from a strain that caused an epidemic in New Zealand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H454501268#H454501268\">",
"     \"Meningococcal vaccines\", section on 'Group B meningococcus vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     NEPHROLOGY AND UROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"    </span>",
"   </p>",
"   <p>",
"    The need for confirmation of the diagnosis of hypertension based on three&nbsp;blood pressure (BP)&nbsp;measurements at separate clinical vists&nbsp;was illustrated in a large cohort study of children cared for in community-based practices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/58\">",
"     58",
"    </a>",
"    ]. In the United States, normative BP percentiles are based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 4",
"    </a>",
"    ). Initial BP measurement was normal (below the 90th percentile), prehypertensive&nbsp;(systolic or diastolic BP between the 90th or 95th percentile)&nbsp;and hypertensive (systolic or diastolic BP &ge;95th percentile) in 82, 13, and 5 percent of children. At follow-up, subsequent hypertensive measurements were observed in only 4 percent of the 10,848 children who had initial hypertensive values. In this cohort, the overall prevalence of hypertension&nbsp;was&nbsp;0.3 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Antenatal hydronephrosis and antibiotic prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review of the literature found that continuous antibiotic prophylaxis (CAP), compared with no treatment, decreased the risk of urinary tract infection (14.6 versus 28.9) in infants with high-grade antenatal hydronephrosis, defined as a Society of Fetal Urology (SFU) grades III and IV (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50549 \" href=\"UTD.htm?32/46/33519\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/59\">",
"     59",
"    </a>",
"    ]. However, CAP was not beneficial in patients with low-grade hydronephrosis (SFU grades I and II) as there was no difference in the rate of urinary tract infections between the treated and control groups (2.2 versus 2.8 percent). These findings support the use of CAP in infants with high-grade hydronephrosis but not in those with a less severe condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H14#H14\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     NEUROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Modified Atkins diet for refractory epilepsy in children",
"    </span>",
"   </p>",
"   <p>",
"    The ketogenic diet is an effective treatment for&nbsp;children with refractory epilepsy, but it generally requires an inpatient hospital admission for initiation and some patients&nbsp;have difficulty&nbsp;adhering to the diet.&nbsp;Observational studies have suggested that the modified Atkins diet, an alternative, less-restrictive&nbsp;dietary therapy, is also effective in reducing seizures.&nbsp;In the&nbsp;first randomized trial to date, 102 children ages 2 to 14 with refractory epilepsy were assigned to receive a modified Atkins diet or no dietary intervention for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/60\">",
"     60",
"    </a>",
"    ]. Treatment with the diet was associated with decreased mean seizure frequency as a percentage of baseline (59 versus 100 percent) and increased proportion of patients with &gt;50 percent reduction in seizure frequency (52 versus 12 percent). These results are similar to those reported for the ketogenic diet and&nbsp;lend further support to the use of dietary therapies in children with refractory epilepsy.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link&amp;anchor=H21468923#H21468923\">",
"     \"The ketogenic diet\", section on 'Modifed Atkins diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Vagus nerve stimulation therapy for epilepsy in children",
"    </span>",
"   </p>",
"   <p>",
"    Vagus nerve stimulation (VNS) is approved by the US Food and Drug Administration (FDA) for adjunctive treatment of refractory partial-onset epilepsy in patients older than age 12, but its use in younger children has not been studied in randomized trials. In a recent randomized controlled trial of 41 patients with medically refractory epilepsy (mean age 11 years, range 3 to 17 years), there was no difference in seizure control between the high-stimulation (treatment) group and the low-stimulation (control) group as measured by the number of patients achieving 50 percent or greater reduction in seizure frequency at 20 weeks (16 percent versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/61\">",
"     61",
"    </a>",
"    ]. These results contrast with many prior observational studies that suggested that VNS was similarly effective in children compared with adolescents and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link&amp;anchor=H6#H6\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\", section on 'Other seizure types and patient populations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Everolimus for the treatment of tuberous sclerosis",
"    </span>",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective for the treatment of brain tumors in patients with tuberous sclerosis complex. The most extensive experience comes from the multicenter EXIST-1 trial of children and adults (median age 9.5 years) with tuberous sclerosis complex and growing subependymal giant cell tumors (SGCTs) who were randomly assigned to treatment with everolimus (n = 78) or placebo (n = 39) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/60/5066/abstract/62\">",
"     62",
"    </a>",
"    ]. At a median follow-up of approximately 10 months, the proportion of patients experiencing a &ge;50 percent reduction in volume of SGCTs was significantly greater for the everolimus group compared with placebo (35 versus 0 percent). In addition, the proportion of subjects with SGCT progression was significantly lower for the everolimus group (0 versus 15 percent). Everolimus treatment was generally well-tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=see_link&amp;anchor=H140858574#H140858574\">",
"     \"Tuberous sclerosis complex: Management\", section on 'Everolimus and mTOR inhibitors'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/1\">",
"      Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013; 368:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/2\">",
"      Myer GD, Sugimoto D, Thomas S, Hewett TE. The influence of age on the effectiveness of neuromuscular training to reduce anterior cruciate ligament injury in female athletes: a meta-analysis. Am J Sports Med 2013; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/3\">",
"      Lee RT, Moorman S, Schneider M, Sigalet DL. Bracing is an effective therapy for pectus carinatum: interim results. J Pediatr Surg 2013; 48:184.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/6\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/8\">",
"      Geva A, Brigger MT. Dexamethasone and tonsillectomy bleeding: a meta-analysis. Otolaryngol Head Neck Surg 2011; 144:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/9\">",
"      Shargorodsky J, Hartnick CJ, Lee GS. Dexamethasone and postoperative bleeding after tonsillectomy and adenotonsillectomy in children: A meta-analysis of prospective studies. Laryngoscope 2012; 122:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/10\">",
"      Plante J, Turgeon AF, Zarychanski R, et al. Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials. BMJ 2012; 345:e5389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/11\">",
"      Gallagher TQ, Hill C, Ojha S, et al. Perioperative dexamethasone administration and risk of bleeding following tonsillectomy in children: a randomized controlled trial. JAMA 2012; 308:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/12\">",
"      Kelleher I, Lynch F, Harley M, et al. Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. Arch Gen Psychiatry 2012; 69:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/13\">",
"      Lindberg DM, Shapiro RA, Laskey AL, et al. Prevalence of abusive injuries in siblings and household contacts of physically abused children. Pediatrics 2012; 130:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/14\">",
"      Miller JM, Lessin HR, American Academy of Pediatrics Section on Ophthalmology, et al. Instrument-based pediatric vision screening policy statement. Pediatrics 2012; 130:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/15\">",
"      Atkinson J, Braddick O, Nardini M, Anker S. Infant hyperopia: detection, distribution, changes and correlates-outcomes from the cambridge infant screening programs. Optom Vis Sci 2007; 84:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/16\">",
"      Kirk VG, Clausen MM, Armitage MD, Arnold RW. Preverbal photoscreening for amblyogenic factors and outcomes in amblyopia treatment: early objective screening and visual acuities. Arch Ophthalmol 2008; 126:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/17\">",
"      Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012; 367:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/18\">",
"      de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/19\">",
"      Trasande L, Attina TM, Blustein J. Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. JAMA 2012; 308:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/20\">",
"      Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/21\">",
"      Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012; 367:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/22\">",
"      Fergusson DA, H&eacute;bert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA 2012; 308:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/23\">",
"      Lucas-Herald A, Butler S, Mactier H, et al. Prevalence and characteristics of rib fractures in ex-preterm infants. Pediatrics 2012; 130:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/24\">",
"      Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/25\">",
"      De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/26\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/27\">",
"      Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med 2013; 47:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/28\">",
"      Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/29\">",
"      Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/30\">",
"      Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/31\">",
"      Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med 2012; 367:1687.",
"     </a>",
"    </li>",
"    <li>",
"     Blumberg SJ, Bramlett MD, Kogan MD, et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. file://www.cdc.gov/nchs/data/nhsr/nhsr065.pdf (Accessed on March 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/33\">",
"      Holmes JF, Lillis K, Monroe D, et al. Identifying Children at Very Low Risk of Clinically Important Blunt Abdominal Injuries. Ann Emerg Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/34\">",
"      Ward NT, Darracq MA, Tomaszewski C, Clark RF. Evidence-based treatment of jellyfish stings in North America and Hawaii. Ann Emerg Med 2012; 60:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/35\">",
"      Krogh C, Biggar RJ, Fischer TK, et al. Bottle-feeding and the Risk of Pyloric Stenosis. Pediatrics 2012; 130:e943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/36\">",
"      Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130:e794.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release. FDA approves new drug for the chronic management of some urea cycle disorders. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337639.htm (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/38\">",
"      Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/39\">",
"      Kimberlin DW, Baley J, Committee on infectious diseases, Committee on fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013; 131:e635.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination, 21 April 2011. file://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/41\">",
"      Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/42\">",
"      Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. file://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/49\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir phosphate) prescribing information. www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/52\">",
"      Early estimates of seasonal influenza vaccine effectiveness &mdash; United States, January 2013. MMWR Morb Mortal Wkly Rep 2013; 62 (Early release):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/53\">",
"      Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/54\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/55\">",
"      Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50 Suppl 2:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/56\">",
"      Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511.",
"     </a>",
"    </li>",
"    <li>",
"     Novartis media releases. Novartis receives EU approval for Bexsero, first vaccine to prevent the leading cause of life-threatening meningitis across Europe. file://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtml (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/58\">",
"      Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics 2013; 131:e415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/59\">",
"      Braga LH, Mijovic H, Farrokhyar F, et al. Antibiotic prophylaxis for urinary tract infections in antenatal hydronephrosis. Pediatrics 2013; 131:e251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/60\">",
"      Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: A randomized controlled trial. Epilepsia 2013; 54:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/61\">",
"      Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol 2012; 54:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/60/5066/abstract/62\">",
"      Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2841 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5066=[""].join("\n");
var outline_f4_60_5066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      GENERAL PEDIATRICS AND ADOLESCENT MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Antibiotics for children with uncomplicated severe acute malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention of anterior cruciate ligament (ACL) injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bracing for pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      New levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute kidney injury after synthetic cannabinoid use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intraoperative glucocorticoids and tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Suicidal risk in adolescents with psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Injuries in children living with an abused child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vision screening with photoscreening or autorefraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Obesity and sugar-sweetened beverages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Obesity and endocrine-disrupting chemicals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEONATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Updated policy statement for retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Respiratory distress syndrome and CPAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Effect of fresh RBCs transfusion in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Osteopenia of prematurity and rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ALLERGY, IMMUNOLOGY, AND RHEUMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Biologic agents for systemic onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chapel Hill Consensus Conference on nomenclature of vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CARDIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Safety of competitive athletic participation in patients with LQTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DERMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Proactive, intermittent therapy for long-term control of atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Guidelines for propranolol treatment for infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Topical ivermectin for pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DEVELOPMENT AND BEHAVIORAL PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevalence of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EMERGENCY MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Very low risk criteria for pediatric intraabdominal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hot water immersion for jellyfish stings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Bottle-feeding and risk for pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Antibiotic exposure and risk for inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      GENETICS AND PEDIATRIC METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      New drug for long term treatment of some urea cycle disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      HEMATOLOGY AND ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Risk of inhibitor development in patients with hemophilia A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      INFECTIOUS DISEASES AND IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Management of asymptomatic neonates exposed to HSV during delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      IV acyclovir shortage in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Combination vaccine for meningococcus and Haemophilus influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Oseltamivir treatment approved for infants &ge;2 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      2012-2013 seasonal influenza vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Vertical transmission of hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Safety and efficacy of influenza vaccination in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Meningococcal serogroup B vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      NEPHROLOGY AND UROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Antenatal hydronephrosis and antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      NEUROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Modified Atkins diet for refractory epilepsy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Vagus nerve stimulation therapy for epilepsy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Everolimus for the treatment of tuberous sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2841|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/46/33519\" title=\"diagnostic image 1\">",
"      SFU grading fetal hydronephr",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10235\" title=\"table 1\">",
"      Designation of genital HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 3\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 4\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=related_link\">",
"      Calcium and phosphorus requirements of newborn infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43016?source=related_link\">",
"      Jellyfish stings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=related_link\">",
"      Levonorgestrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=related_link\">",
"      Pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=related_link\">",
"      Severe malnutrition in children in developing countries: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=related_link\">",
"      Tuberous sclerosis complex: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=related_link\">",
"      Urea cycle disorders: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_60_5067="Treatment pediatric MS";
var content_f4_60_5067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of pediatric multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Glatiramer acetate",
"       </td>",
"       <td>",
"        Copaxone",
"       </td>",
"       <td>",
"        20 mg subcutaneous injection daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon beta-1a",
"       </td>",
"       <td>",
"        Avonex",
"       </td>",
"       <td>",
"        30 mcg intramuscular injection weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon beta-1a",
"       </td>",
"       <td>",
"        Rebif",
"       </td>",
"       <td>",
"        22 mcg or 44 mcg subcutaneous injection three times weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon beta-1b",
"       </td>",
"       <td>",
"        Betaseron",
"       </td>",
"       <td>",
"        8 million IU subcutaneous injection every other day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IU: international units; mcg: micrograms; mg: milligrams.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5067=[""].join("\n");
var outline_f4_60_5067=null;
var title_f4_60_5068="Cytology of follicular thyroid lesions";
var content_f4_60_5068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytopathologic diagnosis of follicular thyroid lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cytologic pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histopathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign macrofollicular fragments",
"       </td>",
"       <td>",
"        <p>",
"         Abundant colloid",
"        </p>",
"        <p>",
"         Predominantly large follicles and flat sheets of follicular cells",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nodular goiter (colloid adenoma)",
"        </p>",
"        <p>",
"         Macrofollicular adenoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follicular lesion or atypia of undetermined significance",
"       </td>",
"       <td>",
"        &nbsp;",
"        <p>",
"         Mixed macrofollicular and microfollicular nodules",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cells with mild nuclear atypia",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Extensive oncocytic (H&uuml;rthle cell) change",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"        <p>",
"         Multinodular goiter",
"        </p>",
"        <p>",
"         Follicular adenoma",
"        </p>",
"        <p>",
"         Follicular cancer",
"        </p>",
"        <p>",
"         Papillary cancer (follicular variant)",
"        </p>",
"        <p>",
"         Hashimoto's thyroiditis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         Follicular neoplasm",
"        </p>",
"        <p>",
"         (microfollicular)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Scant colloid",
"        </p>",
"        <p>",
"         Small microfollicles",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Clusters and clumps of cells with varying pleomorphism",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Microfollicular adenoma",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Follicular carcinoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cells have intranuclear inclusions and clefts",
"       </td>",
"       <td>",
"        Follicular variant of papillary carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5068=[""].join("\n");
var outline_f4_60_5068=null;
var title_f4_60_5069="Effective dose estimates for imaging tests";
var content_f4_60_5069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Representative values and ranges of effective dose estimates reported in the literature for selected radiological studies",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Exam",
"       </td>",
"       <td class=\"subtitle1\">",
"        Representative effective dose value (mSv)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range of reported effective dose values (mSv)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest x-ray PA and lateral",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.05 to 0.24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT chest",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT abdominal",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT pelvis",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary calcium CT*",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        64-slice coronary CTA&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Without tube current modulation",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"       <td class=\"sublist_other\">",
"        12 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        With tube current modulation",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Dual source coronary CTA&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        With tube current modulation",
"       </td>",
"       <td class=\"sublist_other\">",
"        13",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 to 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prospectively triggered coronary CTA",
"        <sup>",
"         [3]",
"        </sup>",
"        &bull;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic invasive coronary angiogram",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2 to 16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous coronary intervention or radiofrequency ablation",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        7 to 57",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CTA: computed tomographic angiography; FDG: fluoro-deoxy glucose; PA: postero-anterior.",
"     <br>",
"      * Data combines prospectively triggered and retrospectively gated protocols. The Writing Group estimates the representative effective dose estimate for prospectively triggered coronary calcium CT scans to be approximately 1 mSv, and for retrospectively gated scans, 3 mSv.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       64-slice MDCT and dual source CT studies published since 2005 only, data include a survey of the literature by the Writing Group.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254.",
"       </li>",
"       <li>",
"        Jakobs TF, Becker CR, Ohnesorge B, et al. Multislice helical CT of the heart with retrospective ECG gating: reduction of radiation exposure by ECG-controlled tube current modulation. Eur Radiol 2002; 12:1081.",
"       </li>",
"       <li>",
"        Earls JP, Berman EL, Urban BA, et al. Prospectively gated transverse coronary CT angiography versus retrospectively gated helical technique: improved image quality and reduced radiation dose. Radiology 2008; 246:742.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Gerber TC, Carr JJ, Arai AE, et al. Ionizing Radiation in Cardiac Imaging: A Science Advisory From the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009; 119:1056-1065. Copyright &copy; 2009 American Heart Association, Inc.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5069=[""].join("\n");
var outline_f4_60_5069=null;
var title_f4_60_5070="Vibrio cases by month";
var content_f4_60_5070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Reported Vibrio cases in the United States in 2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of Vibrio infections (excluding toxigenic V. cholerae) in the United States reported to the Centers for Disease Control each month in 2009 (n = 825).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Cholera and Other Vibrio Illness (COVIS) Annual Summary, 2009. Centers for Disease Control and Prevention. file://www.cdc.gov/nationalsurveillance/cholera_vibrio_surveillance.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_60_5070=[""].join("\n");
var outline_f4_60_5070=null;
var title_f4_60_5071="Contents: Gastrointestinal infections";
var content_f4_60_5071=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastrointestinal infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastrointestinal infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal abscesses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29526\">",
"           Pyogenic liver abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26069\">",
"           AIDS cholangiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/6/42087\">",
"           Endoscopic diagnosis and management of biliary parasitosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bowel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38452\">",
"           Abdominal actinomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29976\">",
"           Approach to the adult with acute diarrhea in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5625\">",
"           Approach to the child with acute diarrhea in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26761\">",
"           Approach to the patient with nontyphoidal Salmonella in a stool culture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/44/1736\">",
"           Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38535\">",
"           Clinical manifestations and diagnosis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14232\">",
"           Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/19/19769\">",
"           Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/48/26376\">",
"           Clinical presentation and diagnosis of rotavirus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/33/21015\">",
"           Clostridium difficile and probiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29305\">",
"           Clostridium difficile in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/18/36137\">",
"           Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20954\">",
"           Clostridium difficile in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31493\">",
"           Cyclospora infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24265\">",
"           Differential diagnosis of microbial foodborne disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26345\">",
"           Epidemiology and causes of acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/10/6313\">",
"           Epidemiology of viral gastroenteritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43241\">",
"           Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13961\">",
"           Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33224\">",
"           Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42008\">",
"           Epidemiology, microbiology, and pathogenesis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42024\">",
"           Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/58/19368\">",
"           Infection with less common Campylobacter species and related bacteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14649\">",
"           Microbiology and epidemiology of salmonellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5065\">",
"           Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/19/18745\">",
"           Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16089\">",
"           Microsporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36073\">",
"           Overview of Vibrio cholerae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/37/19033\">",
"           Pathogenesis of Salmonella gastroenteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29768\">",
"           Pathogenesis of Vibrio cholerae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/6/21607\">",
"           Pathogenesis of typhoid fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37960\">",
"           Pathogenic Escherichia coli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12184\">",
"           Prevention and control of Clostridium difficile in hospital and institutional settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/27/18868\">",
"           Prevention and treatment of viral gastroenteritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29145\">",
"           Travelers' diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39334\">",
"           Treatment and prevention of Shigella infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/40/1670\">",
"           Treatment and prevention of cryptosporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/58/18345\">",
"           Treatment and prevention of typhoid fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/46/745\">",
"           Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/53/43862\">",
"           Tuberculous enteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27125\">",
"           Typhlitis (neutropenic enterocolitis)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32274\">",
"           Clinical microbiology review: Gastrointestinal infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other GI infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/30/33254\">",
"           Pylephlebitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/35/11833\">",
"           Whipple's disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Peritoneal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22617\">",
"           Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7172\">",
"           Clinical manifestations of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12296\">",
"           Diagnosis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17594\">",
"           Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34197\">",
"           Pathogenesis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26248\">",
"           Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3018\">",
"           Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/49/34585\">",
"           Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43241\">",
"           Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/26/41383\">",
"           Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7591\">",
"           Overview of hepatitis A virus infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17223\">",
"           Poliovirus vaccination",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C8BCB9E561-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_60_5071=[""].join("\n");
var outline_f4_60_5071=null;
